The	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
BMRF1	I-DNA
promoter	I-DNA
for	O
early	B-protein
antigen	I-protein
(	O
EA-D	B-protein
)	O
is	O
regulated	O
by	O
the	O
EBV	B-protein
transactivators	I-protein
,	O
BRLF1	B-protein
and	O
BZLF1	B-protein
,	O
in	O
a	O
cell-specific	O
manner	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
early	I-protein
antigen	I-protein
diffuse	I-protein
component	I-protein
(	O
EA-D	B-protein
)	O
is	O
essential	O
for	O
Epstein-Barr	O
virus	B-DNA
DNA	I-DNA
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	B-DNA
(	O
BMRF1	B-DNA
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	B-protein
viral	I-protein
transactivators	I-protein
,	O
BZLF1	B-protein
(	O
Z	B-protein
)	O
and	O
BRLF1	B-protein
(	O
R	B-protein
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O

In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
Z	B-protein
or	O
R	B-protein
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA-D	B-DNA
promoter	I-DNA
activity	O
,	O
whereas	O
both	O
transactivators	B-protein
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O

In	O
epithelial	B-cell_type
cells	I-cell_type
,	O
the	O
Z	B-protein
transactivator	I-protein
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
;	O
the	O
effect	O
of	O
R	B-protein
and	O
Z	B-protein
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	B-protein
alone	O
.	O

Deletional	O
analysis	O
and	O
site-directed	O
mutagenesis	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
demonstrated	O
that	O
in	O
epithelial	B-cell_type
cells	I-cell_type
the	O
potential	O
AP-1	B-DNA
binding	I-DNA
site	I-DNA
plays	O
an	O
essential	O
role	O
in	O
Z	B-protein
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O

In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
only	O
the	O
upstream	B-DNA
sequences	I-DNA
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z/R	B-protein
combination	O
,	O
and	O
the	O
AP-1	B-protein
site	I-protein
is	O
dispensable	O
.	O

These	O
data	O
suggest	O
that	O
EA-D	B-DNA
(	I-DNA
BMRF1	I-DNA
)	I-DNA
promoter	I-DNA
regulation	O
by	O
Z	B-protein
and	O
R	B-protein
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O

JournNAL	NULL
or	NULL
VirOLOGY	NULL
,	NULL
Aug.	NULL
1990	NULL
,	NULL
p.	NULL
3753-3759	NULL
0022-538	NULL
X/90/083753-07	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
Â©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

8	NULL
The	NULL
Epstein-Barr	NULL
Virus	NULL
(	NULL
EBV	NULL
)	NULL
BMRF1	NULL
Promoter	NULL
for	NULL
Early	NULL
Antigen	NULL
(	NULL
EA-D	NULL
)	NULL
Is	NULL
Regulated	NULL
by	NULL
the	NULL
EBV	NULL
Transactivators	NULL
,	NULL
BRLFIl	NULL
and	NULL
BZLF1	NULL
,	NULL
in	NULL
a	NULL
Cell-Specific	NULL
Manner	NULL
ELIZABETH	NULL
A.	NULL
HOLLEY-GUTHRIE	NULL
,	NULL
E.	NULL
BYRD	NULL
QUINLIVAN	NULL
,	NULL
ENG-CHUNG	NULL
MAR	NULL
,	NULL
anp	NULL
SHANNON	NULL
KENNEY*	NULL
Lineberger	NULL
Cancer	NULL
Research	NULL
Center	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
at	NULL
Chapel	NULL
Hill	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
North	NULL
Carolina	NULL
27599-7295	NULL
Received	NULL
6	NULL
February	NULL
1990/Accepted	NULL
8	NULL
May	NULL
1990	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
antigen	NULL
diffuse	NULL
component	NULL
(	NULL
EA-D	NULL
)	NULL
is	NULL
essential	NULL
for	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
polymerase	NULL
activity	NULL
,	NULL
and	NULL
its	NULL
activity	NULL
is	NULL
suppressed	NULL
during	NULL
latent	NULL
infection	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
promoter	NULL
(	NULL
BMRF1	NULL
)	NULL
for	NULL
this	NULL
early	NULL
gene	NULL
by	NULL
studying	NULL
its	NULL
responsiveness	NULL
in	NULL
vitro	NULL
to	NULL
two	NULL
immediate-early	NULL
viral	NULL
transactivators	NULL
,	NULL
BZLF1	NULL
(	NULL
Z	NULL
)	NULL
and	NULL
BRLF1	NULL
(	NULL
R	NULL
)	NULL
,	NULL
focusing	NULL
on	NULL
the	NULL
differences	NULL
in	NULL
response	NULL
in	NULL
lymphoid	NULL
cells	NULL
and	NULL
epithelial	NULL
cells	NULL
.	NULL

In	NULL
lymphoid	NULL
cells	NULL
,	NULL
Z	NULL
or	NULL
R	NULL
alone	NULL
produced	NULL
only	NULL
small	NULL
increases	NULL
in	NULL
EA-D	NULL
promoter	NULL
activity	NULL
,	NULL
whereas	NULL
both	NULL
transactivators	NULL
together	NULL
produced	NULL
a	NULL
large	NULL
stimulatory	NULL
effect	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
,	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
produced	NULL
maximal	NULL
stimulation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
;	NULL
the	NULL
effect	NULL
of	NULL
R	NULL
and	NULL
Z	NULL
together	NULL
was	NULL
no	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
Z	NULL
alone	NULL
.	NULL

Deletional	NULL
analysis	NULL
and	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
demonstrated	NULL
that	NULL
in	NULL
epithelial	NULL
cells	NULL
the	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
Z	NULL
responsiveness	NULL
,	NULL
although	NULL
sequences	NULL
further	NULL
upstream	NULL
are	NULL
also	NULL
important	NULL
.	NULL

In	NULL
lymphoid	NULL
cells	NULL
,	NULL
only	NULL
the	NULL
upstream	NULL
sequences	NULL
are	NULL
required	NULL
for	NULL
transactivation	NULL
by	NULL
the	NULL
Z/R	NULL
combination	NULL
,	NULL
and	NULL
the	NULL
AP-1	NULL
site	NULL
is	NULL
dispensable	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
EA-D	NULL
(	NULL
BMRF1	NULL
)	NULL
promoter	NULL
regulation	NULL
by	NULL
Z	NULL
and	NULL
R	NULL
is	NULL
cell	NULL
type	NULL
specific	NULL
and	NULL
appears	NULL
to	NULL
involve	NULL
different	NULL
mechanisms	NULL
in	NULL
each	NULL
cell	NULL
type	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
a	NULL
herpesvirus	NULL
that	NULL
infects	NULL
primarily	NULL
B	NULL
cells	NULL
and	NULL
epithelial	NULL
cells	NULL
(	NULL
17	NULL
,	NULL
28	NULL
,	NULL
32	NULL
)	NULL
.	NULL

EBV	NULL
infection	NULL
of	NULL
B	NULL
cells	NULL
is	NULL
predominantly	NULL
latent	NULL
,	NULL
whereas	NULL
epithelial-cell	NULL
infection	NULL
is	NULL
often	NULL
productive	NULL
(	NULL
28	NULL
)	NULL
,	NULL
raising	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
there	NULL
are	NULL
different	NULL
mechanisms	NULL
for	NULL
regulation	NULL
of	NULL
viral	NULL
expression	NULL
in	NULL
lymphoid	NULL
and	NULL
epithelial	NULL
cells	NULL
.	NULL

Overexpression	NULL
of	NULL
the	NULL
immediate-early	NULL
(	NULL
IE	NULL
)	NULL
EBV	NULL
gene	NULL
product	NULL
,	NULL
BZLF1	NULL
,	NULL
in	NULL
EBV-infected	NULL
B	NULL
cells	NULL
is	NULL
sufficient	NULL
to	NULL
convert	NULL
latent	NULL
expression	NULL
to	NULL
productive	NULL
infection	NULL
(	NULL
10	NULL
,	NULL
13	NULL
,	NULL
29	NULL
,	NULL
33	NULL
)	NULL
.	NULL

The	NULL
BZLFl	NULL
gene	NULL
(	NULL
Z	NULL
)	NULL
encodes	NULL
a	NULL
34-	NULL
to	NULL
38-kilodalton	NULL
nuclear	NULL
protein	NULL
(	NULL
the	NULL
Z	NULL
protein	NULL
)	NULL
which	NULL
has	NULL
sequence	NULL
similarity	NULL
to	NULL
the	NULL
DNA-binding	NULL
site	NULL
of	NULL
the	NULL
c-fos	NULL
protein	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
7	NULL
)	NULL
,	NULL
although	NULL
there	NULL
is	NULL
no	NULL
potential	NULL
leucine	NULL
zipper	NULL
(	NULL
36	NULL
)	NULL
in	NULL
the	NULL
Z	NULL
protein	NULL
.	NULL

Exactly	NULL
how	NULL
the	NULL
Z	NULL
protein	NULL
binds	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
,	NULL
or	NULL
whether	NULL
binding	NULL
of	NULL
Z	NULL
to	NULL
AP-1	NULL
or	NULL
closely	NULL
related	NULL
sites	NULL
is	NULL
always	NULL
required	NULL
for	NULL
transactivation	NULL
of	NULL
target	NULL
promoters	NULL
,	NULL
is	NULL
still	NULL
unknown	NULL
.	NULL

Although	NULL
the	NULL
Z	NULL
protein	NULL
appears	NULL
to	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
determining	NULL
whether	NULL
EBV	NULL
infection	NULL
is	NULL
latent	NULL
or	NULL
productive	NULL
,	NULL
the	NULL
disruption	NULL
of	NULL
latency	NULL
is	NULL
likely	NULL
to	NULL
involve	NULL
other	NULL
EBV	NULL
transactivators	NULL
.	NULL

Two	NULL
other	NULL
EBV	NULL
IE	NULL
gene	NULL
products	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
encode	NULL
transactivator	NULL
functions	NULL
.	NULL

The	NULL
BMLF1	NULL
gene	NULL
product	NULL
has	NULL
been	NULL
shown	NULL
by	NULL
several	NULL
groups	NULL
to	NULL
transactivate	NULL
a	NULL
number	NULL
of	NULL
homologous	NULL
and	NULL
heterologous	NULL
promoters	NULL
(	NULL
4	NULL
,	NULL
14	NULL
,	NULL
16	NULL
,	NULL
24	NULL
,	NULL
37	NULL
)	NULL
linked	NULL
to	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
BMLFI1	NULL
effect	NULL
is	NULL
reporter	NULL
gene	NULL
dependent	NULL
and	NULL
does	NULL
not	NULL
result	NULL
in	NULL
significantly	NULL
increased	NULL
levels	NULL
of	NULL
mRNA	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
BMLF1l	NULL
gene	NULL
in	NULL
induction	NULL
of	NULL
lytic	NULL
viral	NULL
infection	NULL
remains	NULL
unknown	NULL
.	NULL

The	NULL
BRLF1	NULL
gene	NULL
also	NULL
encodes	NULL
an	NULL
IE	NULL
transactivator	NULL
function	NULL
(	NULL
1	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

The	NULL
BRLF1	NULL
gene	NULL
product	NULL
is	NULL
a	NULL
94-	NULL
to	NULL
98-kDa	NULL
protein	NULL
which	NULL
localizes	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
cytoplasm	NULL
(	NULL
5	NULL
,	NULL
26	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
cDNA	NULL
analysis	NULL
,	NULL
the	NULL
BRLF1	NULL
protein	NULL
(	NULL
R	NULL
)	NULL
is	NULL
derived	NULL
from	NULL
a	NULL
bicistronic	NULL
mRNA	NULL
which	NULL
also	NULL
encodes	NULL
the	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

3753	NULL
Z	NULL
protein	NULL
(	NULL
25	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
is	NULL
tightly	NULL
linked	NULL
.	NULL

The	NULL
R	NULL
transactivator	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
Z	NULL
,	NULL
can	NULL
not	NULL
disrupt	NULL
viral	NULL
latency	NULL
when	NULL
transfected	NULL
and	NULL
overexpressed	NULL
in	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Several	NULL
EBV	NULL
early	NULL
promoters	NULL
are	NULL
transactivated	NULL
by	NULL
either	NULL
Z	NULL
or	NULL
R.	NULL
The	NULL
genes	NULL
activated	NULL
by	NULL
Z	NULL
include	NULL
BMLF1	NULL
,	NULL
BMRF1	NULL
,	NULL
the	NULL
BZLF1	NULL
gene	NULL
itself	NULL
,	NULL
and	NULL
the	NULL
divergent	NULL
promoter	NULL
(	NULL
DR/DL	NULL
)	NULL
(	NULL
1-5	NULL
,	NULL
12	NULL
,	NULL
13	NULL
,	NULL
23	NULL
,	NULL
25	NULL
,	NULL
31	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Z-responsive	NULL
elements	NULL
in	NULL
these	NULL
promoters	NULL
have	NULL
been	NULL
mapped	NULL
within	NULL
100	NULL
base	NULL
pairs	NULL
(	NULL
bp	NULL
)	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
,	NULL
and	NULL
the	NULL
response	NULL
elements	NULL
have	NULL
included	NULL
AP-1	NULL
(	NULL
or	NULL
closely	NULL
related	NULL
)	NULL
binding	NULL
sites	NULL
.	NULL

The	NULL
R	NULL
transactivator	NULL
activates	NULL
the	NULL
DR	NULL
promoter	NULL
and	NULL
the	NULL
BMLF1	NULL
promoter	NULL
(	NULL
1-3	NULL
,	NULL
5	NULL
,	NULL
12	NULL
)	NULL
.	NULL

The	NULL
R-responsive	NULL
regions	NULL
in	NULL
both	NULL
of	NULL
these	NULL
promoters	NULL
reside	NULL
within	NULL
upstream	NULL
enhancer	NULL
elements	NULL
,	NULL
and	NULL
both	NULL
of	NULL
these	NULL
R-responsive	NULL
elements	NULL
contain	NULL
the	NULL
same	NULL
14-bp	NULL
sequence	NULL
motif	NULL
,	NULL
CCGTGGAC/GAATGTC	NULL
.	NULL

Whether	NULL
the	NULL
R	NULL
transactivator	NULL
binds	NULL
to	NULL
DNA	NULL
is	NULL
unknown	NULL
at	NULL
present	NULL
.	NULL

In	NULL
the	NULL
work	NULL
described	NULL
in	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
have	NULL
studied	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
EBV	NULL
BMRF1	NULL
early	NULL
promoter	NULL
,	NULL
EA-D	NULL
.	NULL

The	NULL
BMRFl	NULL
gene	NULL
encodes	NULL
the	NULL
early	NULL
antigen	NULL
diffuse	NULL
(	NULL
EA-D	NULL
)	NULL
protein	NULL
,	NULL
which	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
viral	NULL
DNA	NULL
polymerase	NULL
activity	NULL
(	NULL
22	NULL
)	NULL
.	NULL

EA-D	NULL
activity	NULL
is	NULL
suppressed	NULL
in	NULL
latent	NULL
infection	NULL
and	NULL
reactivated	NULL
during	NULL
productive	NULL
infection	NULL
(	NULL
6	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
the	NULL
EA-D	NULL
promoter	NULL
is	NULL
differentially	NULL
regulated	NULL
in	NULL
lymphoid	NULL
and	NULL
epithelial	NULL
cells	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
,	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
transactivate	NULL
the	NULL
EA-D	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
Z	NULL
transactivation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
cells	NULL
is	NULL
inefficient	NULL
unless	NULL
the	NULL
R	NULL
transactivator	NULL
is	NULL
also	NULL
present	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
the	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
EA-D	NULL
promoter	NULL
is	NULL
essential	NULL
for	NULL
Z-induced	NULL
transactivation	NULL
in	NULL
epithelial	NULL
cells	NULL
,	NULL
but	NULL
is	NULL
not	NULL
required	NULL
for	NULL
the	NULL
Z/R	NULL
combined	NULL
effect	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
used	NULL
include	NULL
the	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
B-cell	NULL
line	NULL
(	NULL
Louckes	NULL
)	NULL
,	NULL
a	NULL
T-cell	NULL
line	NULL
3754	NULL
HOLLEY-GUTHRIE	NULL
ET	NULL
AL	NULL
.	NULL

``	NULL
3	NULL
Xk	NULL
G	NULL
n.5	NULL
a	NULL
BMRF1	NULL
BomH	NULL
!	NULL

BstEI	NULL
Â¢Â§	NULL
mT	NULL
a	NULL
Sou3A	NULL
@	NULL
me	NULL
u-Promoter	NULL
79,537	NULL
7	NULL
a	NULL
19,898	NULL
a	NULL
&	NULL
<	NULL
4	NULL
|-Plasmid	NULL
Insert	NULL
BamH1	NULL
Rsoft	NULL
~	NULL
>	NULL
pEA	NULL
(	NULL
-331/+1	NULL
)	NULL
'ââââ4	NULL
$	NULL
Â°	NULL
79,537	NULL
79,870	NULL
BstEX	NULL
pEA	NULL
(	NULL
-265	NULL
/+1	NULL
)	NULL
mo-79,604	NULL
79,870	NULL
Sou3A	NULL
Sau3A	NULL
pEA	NULL
(	NULL
-214/+29	NULL
)	NULL
79,655	NULL
79,898	NULL
BstX1	NULL
-	NULL
Rsal	NULL
EA	NULL
(	NULL
-79/	NULL
+1	NULL
E	NULL
--	NULL
A4	NULL
pEA	NULL
(	NULL
-79/	NULL
+1	NULL
)	NULL
79,790	NULL
79,870	NULL
HinF1	NULL
S	NULL
pEA	NULL
(	NULL
-62/+29	NULL
)	NULL
mfl	NULL
Sauce	NULL
79,807	NULL
79,898	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Construction	NULL
of	NULL
pEA-CAT	NULL
deletions	NULL
.	NULL

The	NULL
parent	NULL
pEA-CAT	NULL
construct	NULL
contains	NULL
the	NULL
EBV	NULL
BamHI-Rsal	NULL
fragment	NULL
(	NULL
EBV	NULL
nucleotides	NULL
79537	NULL
to	NULL
79898	NULL
)	NULL
linked	NULL
to	NULL
CAT	NULL
.	NULL

A	NULL
series	NULL
of	NULL
5Â°	NULL
deletion	NULL
mutants	NULL
were	NULL
constructed	NULL
by	NULL
cutting	NULL
at	NULL
the	NULL
indicated	NULL
restriction	NULL
endonuclease	NULL
site	NULL
,	NULL
blunt	NULL
ending	NULL
with	NULL
T4	NULL
polymerase	NULL
or	NULL
Klenow	NULL
enzymes	NULL
,	NULL
and	NULL
religating	NULL
.	NULL

The	NULL
TATA	NULL
box	NULL
and	NULL
a	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
Jurkat	NULL
)	NULL
,	NULL
a	NULL
cervical	NULL
epithelial-cell	NULL
line	NULL
(	NULL
HeLa	NULL
)	NULL
,	NULL
and	NULL
a	NULL
laryn-geal	NULL
epithelial-cell	NULL
line	NULL
(	NULL
HEp-2	NULL
)	NULL
.	NULL

All	NULL
lymphoid	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

HeLa	NULL
and	NULL
HEp-2	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
H	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

DNA	NULL
transfections	NULL
.	NULL

Plasmid	NULL
DNA	NULL
was	NULL
purified	NULL
through	NULL
two	NULL
sequential	NULL
cesium	NULL
chloride	NULL
gradients	NULL
.	NULL

DNA	NULL
was	NULL
transfected	NULL
into	NULL
both	NULL
lymphoid	NULL
and	NULL
epithelial	NULL
cell	NULL
lines	NULL
by	NULL
electroporation	NULL
(	NULL
34	NULL
)	NULL
.	NULL

For	NULL
each	NULL
condition	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
shocked	NULL
at	NULL
1,500	NULL
V	NULL
with	NULL
the	NULL
Zapper	NULL
electroporation	NULL
unit	NULL
(	NULL
Medical	NULL
Electronics	NULL
Shop	NULL
,	NULL
University	NULL
of	NULL
Wisconsin	NULL
)	NULL
.	NULL

Epithelial	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
suspended	NULL
into	NULL
RPMI	NULL
1640	NULL
medium	NULL
for	NULL
electro-poration	NULL
.	NULL

>	NULL
EBV-CAT	NULL
plasmids	NULL
.	NULL

EBV-CAT	NULL
plasmids	NULL
were	NULL
constructed	NULL
by	NULL
inserting	NULL
EBV	NULL
promoter	NULL
sequences	NULL
into	NULL
the	NULL
Bg/ll	NULL
site	NULL
of	NULL
the	NULL
plasmid	NULL
vector	NULL
pCAT3M	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
pCAT3M	NULL
contains	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
and	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
polyadenylation	NULL
site	NULL
but	NULL
no	NULL
eucaryotic	NULL
promoter	NULL
element	NULL
.	NULL

The	NULL
plasmid	NULL
pM-CAT	NULL
(	NULL
12	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
de-scribed	NULL
,	NULL
contains	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
EBV	NULL
IE	NULL
gene	NULL
,	NULL
BMLF1	NULL
,	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

The	NULL
pEA-CAT	NULL
plasmid	NULL
,	NULL
which	NULL
has	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
early	NULL
EA-D	NULL
gene	NULL
,	NULL
contains	NULL
the	NULL
333-bp	NULL
EBV	NULL
BamHI-Rsal	NULL
fragment	NULL
(	NULL
nucleotides	NULL
79537	NULL
to	NULL
79898	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

5	NULL
'	NULL
deletion	NULL
mutants	NULL
of	NULL
pEA-CAT	NULL
were	NULL
made	NULL
by	NULL
cutting	NULL
with	NULL
the	NULL
restriction	NULL
enzymes	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
blunt	NULL
ending	NULL
with	NULL
T4	NULL
polymerase	NULL
or	NULL
the	NULL
Klenow	NULL
enzymes	NULL
,	NULL
and	NULL
religating	NULL
to	NULL
pCAT3M	NULL
.	NULL

The	NULL
genome	NULL
map	NULL
locations	NULL
of	NULL
each	NULL
construct	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
plasmid	NULL
pEA-BS-CAT	NULL
was	NULL
made	NULL
(	NULL
for	NULL
use	NULL
in	NULL
in	NULL
vitro	NULL
site-directed	NULL
mutagenesis	NULL
)	NULL
by	NULL
inserting	NULL
the	NULL
Xbal-BamHI	NULL
fragment	NULL
from	NULL
pEA-CAT	NULL
(	NULL
which	NULL
contains	NULL
the	NULL
complete	NULL
EA	NULL
promoter	NULL
sequences	NULL
,	NULL
the	NULL
CAT	NULL
gene	NULL
,	NULL
and	NULL
the	NULL
polyadenylation	NULL
site	NULL
)	NULL
into	NULL
the	NULL
Xbal-BamHI	NULL
site	NULL
of	NULL
the	NULL
M13	NULL
Bluescript	NULL
SK+	NULL
plasmid	NULL
(	NULL
Stratagene	NULL
Inc.	NULL
)	NULL
.	NULL

EBV	NULL
transactivating	NULL
plasmids	NULL
.	NULL

The	NULL
pEBV-ZIE	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
contains	NULL
the	NULL
BamHI	NULL
Z	NULL
gene	NULL
fragment	NULL
(	NULL
nucleotides	NULL
101741	NULL
to	NULL
103947	NULL
)	NULL
in	NULL
the	NULL
pGem2-based	NULL
vector	NULL
pHD1013	NULL
(	NULL
15	NULL
)	NULL
,	NULL
such	NULL
that	NULL
the	NULL
BZLF1	NULL
gene	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
strong	NULL
human	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
IE	NULL
promoter	NULL
.	NULL

The	NULL
pEBV-RZ	NULL
J.	NULL
Viror	NULL
.	NULL

phD1O13	NULL
Q2	NULL
BomH	NULL
//	NULL
Dan	NULL
z	NULL
~	NULL
-	NULL
~	NULL
V	NULL
,	NULL
N\	NULL
â	NULL
|	NULL
Plasmid	NULL
E	NULL
Bgill	NULL
BRLFi	NULL
BZLF1	NULL
m	NULL
Bgill	NULL
_-_	NULL
--	NULL
-	NULL
Â»	NULL
--	NULL
Â»	NULL
pEBV-RZ	NULL
--	NULL
-	NULL
_-_	NULL
___	NULL
105,412	NULL
101,351	NULL
Bgil	NULL
Hind	NULL
HT	NULL
pEBV-RIE	NULL
i	NULL
--	NULL
--	NULL
--	NULL
-105,412	NULL
103,080	NULL
EBV	NULL
-Z1â¬	NULL
BamH1	NULL
BamH1	NULL
P	NULL
103,947	NULL
101,741	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Construction	NULL
of	NULL
the	NULL
EBV	NULL
transactivator	NULL
plasmids	NULL
.	NULL

The	NULL
pEBV-ZIE	NULL
transactivator	NULL
plasmid	NULL
was	NULL
made	NULL
by	NULL
placing	NULL
the	NULL
BamHI	NULL
Z	NULL
fragment	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
pHD1013	NULL
.	NULL

This	NULL
places	NULL
the	NULL
BZLFI1	NULL
gene	NULL
under	NULL
control	NULL
of	NULL
the	NULL
strong	NULL
human	NULL
CMV	NULL
IE	NULL
promoter	NULL
.	NULL

The	NULL
pEBV-RZ	NULL
transactivator	NULL
construct	NULL
contains	NULL
the	NULL
Bg/ll	NULL
J	NULL
fragment	NULL
inserted	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
pHD1013	NULL
.	NULL

pEBV-RZ	NULL
places	NULL
both	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivating	NULL
proteins	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
CMV	NULL
IE	NULL
promoter	NULL
.	NULL

The	NULL
pEBV-RIE	NULL
plasmid	NULL
contains	NULL
a	NULL
HindlII-HindIII	NULL
fragment	NULL
from	NULL
pEBV-RZ	NULL
containing	NULL
the	NULL
BRLF1	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
CMV	NULL
IE	NULL
promoter	NULL
ligated	NULL
into	NULL
a	NULL
pUC-18	NULL
vector	NULL
.	NULL

plasmid	NULL
contains	NULL
both	NULL
the	NULL
BRLF1l	NULL
(	NULL
R	NULL
)	NULL
and	NULL
BZLFl	NULL
(	NULL
Z	NULL
)	NULL
transactivators	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
CMV-IE	NULL
promoter	NULL
(	NULL
both	NULL
gene	NULL
products	NULL
can	NULL
be	NULL
made	NULL
from	NULL
a	NULL
bicistronic	NULL
mRNA	NULL
)	NULL
.	NULL

This	NULL
plasmid	NULL
has	NULL
the	NULL
4,061-bp	NULL
Be/ll-Bailll	NULL
fragment	NULL
(	NULL
EBV	NULL
nucleotides	NULL
101351	NULL
to	NULL
105412	NULL
)	NULL
inserted	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
the	NULL
vector	NULL
pHD1013	NULL
.	NULL

In	NULL
the	NULL
pEBV-RIE	NULL
plasmid	NULL
,	NULL
a	NULL
HindIII-HindIII	NULL
fragment	NULL
from	NULL
pEBV-RZ	NULL
(	NULL
which	NULL
contains	NULL
the	NULL
BRLF1l	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
CMV-IE	NULL
promoter	NULL
)	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
pUCI18	NULL
vector	NULL
.	NULL

The	NULL
construction	NULL
of	NULL
these	NULL
EBV	NULL
transactivator	NULL
plasmids	NULL
is	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
as	NULL
described	NULL
above	NULL
.	NULL

At	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
a	NULL
cell	NULL
extract	NULL
was	NULL
prepared	NULL
and	NULL
incubated	NULL
at	NULL
37Â°C	NULL
with	NULL
[	NULL
'*C	NULL
)	NULL
chloramphenicol	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
acetyl	NULL
coenzyme	NULL
A	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
percent	NULL
acetylation	NULL
of	NULL
chloramphenicol	NULL
was	NULL
quantitated	NULL
by	NULL
thin-layer	NULL
chromatogra-phy	NULL
followed	NULL
by	NULL
autoradiography	NULL
and	NULL
scintillation	NULL
counting	NULL
.	NULL

If	NULL
results	NULL
were	NULL
not	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
(	NULL
less	NULL
than	NULL
70	NULL
%	NULL
chloramphenicol	NULL
acetylation	NULL
)	NULL
,	NULL
CAT	NULL
assays	NULL
were	NULL
repeated	NULL
with	NULL
less	NULL
extract	NULL
.	NULL

RNA	NULL
analysis	NULL
.	NULL

To	NULL
quantitate	NULL
CAT	NULL
mRNA	NULL
,	NULL
we	NULL
prepared	NULL
cytoplasmic	NULL
RNA	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
8	NULL
)	NULL
.	NULL

A	NULL
20-bp	NULL
oligonucleotide	NULL
primer	NULL
homologous	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
the	NULL
region	NULL
15	NULL
to	NULL
34	NULL
bp	NULL
downstream	NULL
of	NULL
the	NULL
ATG	NULL
codon	NULL
was	NULL
synthesized	NULL
and	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
y	NULL
>	NULL
P	NULL
]	NULL
JATP	NULL
.	NULL

Labeled	NULL
oligonucleotide	NULL
(	NULL
10Â°	NULL
cpm	NULL
)	NULL
was	NULL
hybridized	NULL
overnight	NULL
with	NULL
cytoplasmic	NULL
RNA	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
80	NULL
%	NULL
formamide	NULL
,	NULL
40	NULL
mM	NULL
PIPES	NULL
[	NULL
piperazine-N	NULL
,	NULL
N'-bis	NULL
(	NULL
2-ethanesulfonic	NULL
acid	NULL
)	NULL
}	NULL
,	NULL
400	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
.	NULL

Primer	NULL
extension	NULL
(	NULL
18	NULL
)	NULL
was	NULL
performed	NULL
at	NULL
42Â°C	NULL
for	NULL
90	NULL
min	NULL
with	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
primer	NULL
extension	NULL
products	NULL
were	NULL
electrophoresed	NULL
on	NULL
a	NULL
6	NULL
%	NULL
acrylamide-7	NULL
M	NULL
urea	NULL
gel	NULL
.	NULL

In	NULL
vitro	NULL
site-directed	NULL
mutagenesis	NULL
.	NULL

Mutants	NULL
were	NULL
made	NULL
by	NULL
using	NULL
the	NULL
Bio-Rad	NULL
Muta-Gene	NULL
phagemid	NULL
in	NULL
vitro	NULL
mutagenesis	NULL
kit	NULL
,	NULL
based	NULL
on	NULL
a	NULL
method	NULL
described	NULL
by	NULL
Kunkel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
Jurkat	NULL
Jurkat	NULL
Louckes	NULL
M	NULL
CAT	NULL
--	NULL
r-pEA	NULL
(	NULL
-331/+1	NULL
)	NULL
-7	NULL
pHD	NULL
Z	NULL
Ro	NULL
Z+R	NULL
pHD	NULL
Z	NULL
R	NULL
Z+R	NULL
%	NULL
Â®	NULL
PR	NULL
e	NULL
e	NULL
e	NULL
eo	NULL
0	NULL
o	NULL
e	NULL
o	NULL
@	NULL
)	NULL
29	NULL
586	NULL
587	NULL
0	NULL
16	NULL
43	NULL
m	NULL
0	NULL
16	NULL
13	NULL
209	NULL
HeLa	NULL
HeL	NULL
HEp-2	NULL
M	NULL
CAT	NULL
pEA	NULL
(	NULL
-331/+1	NULL
)	NULL
-	NULL
r-pEA	NULL
(	NULL
-331/+1	NULL
)	NULL
-pHD	NULL
Z	NULL
_	NULL
R	NULL
Z+R	NULL
pHD	NULL
Z	NULL
R	NULL
RZ	NULL
Â©	NULL
-e	NULL
@	NULL
@	NULL
*	NULL
â¬	NULL
â¬	NULL
Â¢	NULL
â¬	NULL
6	NULL
e	NULL
6	NULL
0	NULL
S18	NULL
7.7	NULL
474	NULL
1.0	NULL
310	NULL
1.4	NULL
20.7	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
transactivators	NULL
on	NULL
the	NULL
BMRF1	NULL
(	NULL
EA-D	NULL
)	NULL
early	NULL
promoter	NULL
versus	NULL
the	NULL
BMLFI1	NULL
IE	NULL
promoter	NULL
.	NULL

A	NULL
5-ug	NULL
portion	NULL
of	NULL
either	NULL
the	NULL
pM-CAT	NULL
plasmid	NULL
(	NULL
12	NULL
)	NULL
(	NULL
which	NULL
contains	NULL
the	NULL
primarily	NULL
R-responsive	NULL
BMLF1	NULL
promoter	NULL
)	NULL
or	NULL
the	NULL
pEA-CAT	NULL
plasmid	NULL
(	NULL
-331	NULL
to	NULL
+1	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
early	NULL
EA-D	NULL
promoter	NULL
,	NULL
was	NULL
cotransfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
either	NULL
pEBV-ZIE	NULL
(	NULL
which	NULL
encodes	NULL
Z	NULL
)	NULL
,	NULL
pEBV-RIE	NULL
(	NULL
which	NULL
encodes	NULL
R	NULL
)	NULL
,	NULL
or	NULL
both	NULL
transactivators	NULL
together	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
)	NULL
.	NULL

CAT	NULL
assay	NULL
results	NULL
are	NULL
presented	NULL
as	NULL
fold	NULL
induction	NULL
over	NULL
basal	NULL
levels	NULL
.	NULL

In	NULL
lymphoid	NULL
cells	NULL
(	NULL
Louckes	NULL
and	NULL
Jurkat	NULL
)	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
R	NULL
and	NULL
Z	NULL
is	NULL
required	NULL
for	NULL
maximal	NULL
stimulation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
,	NULL
whereas	NULL
R	NULL
alone	NULL
is	NULL
sufficient	NULL
for	NULL
maximal	NULL
stimulation	NULL
of	NULL
the	NULL
BMLF	NULL
]	NULL
construct	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
(	NULL
HeLa	NULL
and	NULL
HEp-2	NULL
)	NULL
,	NULL
Z	NULL
alone	NULL
produces	NULL
maximal	NULL
transactivation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
,	NULL
whereas	NULL
R	NULL
alone	NULL
is	NULL
sufficient	NULL
for	NULL
maximal	NULL
stimulation	NULL
of	NULL
the	NULL
BMLF1	NULL
promoter	NULL
.	NULL

Mutants	NULL
were	NULL
made	NULL
by	NULL
using	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
complementary	NULL
to	NULL
the	NULL
region	NULL
to	NULL
be	NULL
altered	NULL
except	NULL
for	NULL
a	NULL
limited	NULL
internal	NULL
mismatch	NULL
.	NULL

For	NULL
screening	NULL
possible	NULL
mutants	NULL
,	NULL
synthetic	NULL
oligonucleotides	NULL
were	NULL
created	NULL
such	NULL
that	NULL
in	NULL
vitro	NULL
mutations	NULL
would	NULL
create	NULL
a	NULL
new	NULL
Pvull	NULL
restriction	NULL
site	NULL
which	NULL
allows	NULL
each	NULL
possible	NULL
mutant	NULL
to	NULL
be	NULL
analyzed	NULL
by	NULL
digestion	NULL
with	NULL
restriction	NULL
endonucleases	NULL
.	NULL

Following	NULL
initial	NULL
screening	NULL
,	NULL
potential	NULL
mutants	NULL
were	NULL
sequenced	NULL
with	NULL
the	NULL
Sequenase	NULL
2.0	NULL
enzyme	NULL
sequencing	NULL
kit	NULL
(	NULL
United	NULL
States	NULL
Biochemical	NULL
Corp.	NULL
)	NULL
to	NULL
identify	NULL
the	NULL
mutation	NULL
.	NULL

RESULTS	NULL
The	NULL
EA-D	NULL
promoter	NULL
is	NULL
differentially	NULL
regulated	NULL
in	NULL
lymphoid	NULL
and	NULL
epithelial-cell	NULL
types	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
the	NULL
EA-D	NULL
promoter	NULL
can	NULL
be	NULL
stimulated	NULL
in	NULL
both	NULL
EBV-positive	NULL
and	NULL
EBV-negative	NULL
cell	NULL
lines	NULL
by	NULL
cotransfection	NULL
with	NULL
the	NULL
Z	NULL
transactivator	NULL
plasmid	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
transactivators	NULL
alone	NULL
and	NULL
in	NULL
combination	NULL
on	NULL
EA-D	NULL
promoter	NULL
activity	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

Figure	NULL
3	NULL
illustrates	NULL
representative	NULL
CAT	NULL
assays	NULL
in	NULL
which	NULL
the	NULL
pEA-CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
into	NULL
various	NULL
cell	NULL
types	NULL
with	NULL
either	NULL
the	NULL
pEBV-ZIE	NULL
plasmid	NULL
(	NULL
which	NULL
encodes	NULL
BZLF1	NULL
)	NULL
or	NULL
the	NULL
pEBV-RIE	NULL
plasmid	NULL
(	NULL
which	NULL
encodes	NULL
BRLF1	NULL
)	NULL
,	NULL
or	NULL
both	NULL
transactivators	NULL
together	NULL
.	NULL

In	NULL
either	NULL
B	NULL
or	NULL
T	NULL
lymphoid	NULL
cell	NULL
lines	NULL
(	NULL
Louckes	NULL
and	NULL
Jurkat	NULL
)	NULL
,	NULL
the	NULL
EA-CAT	NULL
promoter	NULL
activity	NULL
was	NULL
only	NULL
slightly	NULL
increased	NULL
CELL-SPECIFIC	NULL
REGULATION	NULL
OF	NULL
AN	NULL
EBV	NULL
PROMOTER	NULL
3755	NULL
on	NULL
cotransfection	NULL
with	NULL
either	NULL
Z	NULL
or	NULL
R.	NULL
However	NULL
,	NULL
when	NULL
pEA-CAT	NULL
was	NULL
cotransfected	NULL
with	NULL
both	NULL
transactivators	NULL
together	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
a	NULL
large	NULL
stimulatory	NULL
effect	NULL
was	NULL
obtained	NULL
.	NULL

This	NULL
synergistic	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
together	NULL
was	NULL
observed	NULL
with	NULL
either	NULL
the	NULL
pEBV-ZIE	NULL
and	NULL
pEBV-RIE	NULL
plasmids	NULL
in	NULL
combination	NULL
or	NULL
the	NULL
pEBV-RZ	NULL
plasmid	NULL
alone	NULL
,	NULL
which	NULL
expresses	NULL
the	NULL
bicistronic	NULL
Z/R	NULL
mRNA	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
plasmid	NULL
pM-CAT	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
EBV	NULL
BMLF1	NULL
gene	NULL
and	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
be	NULL
primarily	NULL
R	NULL
responsive	NULL
(	NULL
12	NULL
)	NULL
,	NULL
is	NULL
transactivated	NULL
equally	NULL
well	NULL
by	NULL
either	NULL
R	NULL
alone	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
epithelial-cell	NULL
lines	NULL
Hela	NULL
and	NULL
HEp-2	NULL
,	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
produced	NULL
a	NULL
large	NULL
stimulatory	NULL
effect	NULL
on	NULL
pEA-CAT	NULL
activity	NULL
.	NULL

As	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
the	NULL
R	NULL
transactivator	NULL
alone	NULL
produced	NULL
only	NULL
a	NULL
small	NULL
effect	NULL
.	NULL

When	NULL
both	NULL
transactivators	NULL
were	NULL
cotransfected	NULL
into	NULL
epithelial	NULL
cells	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
together	NULL
upon	NULL
EA-CAT	NULL
activity	NULL
was	NULL
no	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
Z	NULL
alone	NULL
.	NULL

The	NULL
pM-CAT	NULL
plasmid	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
was	NULL
efficiently	NULL
transactivated	NULL
by	NULL
either	NULL
R	NULL
alone	NULL
or	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
combination	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
activate	NULL
EA-D	NULL
promoter	NULL
activity	NULL
maximally	NULL
in	NULL
epithelial	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
both	NULL
Z	NULL
and	NULL
R	NULL
are	NULL
required	NULL
for	NULL
efficient	NULL
EA-D	NULL
promoter	NULL
transactivation	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

RNA	NULL
analysis	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
both	NULL
the	NULL
Z-	NULL
and	NULL
R-induced	NULL
transactivation	NULL
of	NULL
reporter	NULL
gene	NULL
coristructs	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
similar	NULL
increase	NULL
in	NULL
steady-state	NULL
RNA	NULL
levels	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
Z/R	NULL
transactivator	NULL
combination	NULL
on	NULL
the	NULL
steady-state	NULL
level	NULL
of	NULL
pEA-CAT	NULL
RNA	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
pEA-CAT	NULL
construct	NULL
was	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
either	NULL
pHD1013	NULL
(	NULL
lane	NULL
B	NULL
)	NULL
or	NULL
the	NULL
pEBV-RZ	NULL
transactivator	NULL
construct	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
.	NULL

Lane	NULL
A	NULL
contains	NULL
untransfected	NULL
Jurkat	NULL
RNA	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
harvested	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
and	NULL
hybridized	NULL
to	NULL
a	NULL
y-*P-labeled	NULL
primer	NULL
homologous	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
sequence	NULL
15	NULL
to	NULL
34	NULL
bp	NULL
downstream	NULL
of	NULL
the	NULL
ATG	NULL
codon	NULL
,	NULL
and	NULL
primer	NULL
extension	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Primer	NULL
extension	NULL
analysis	NULL
clearly	NULL
demonstrated	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
steady-state	NULL
level	NULL
of	NULL
pEA-CAT	NULL
mRNA	NULL
after	NULL
cotransfection	NULL
with	NULL
the	NULL
Z/R	NULL
transactivators	NULL
.	NULL

The	NULL
mRNA	NULL
start	NULL
site	NULL
,	NULL
which	NULL
mapped	NULL
to	NULL
EBV	NULL
sequence	NULL
79897	NULL
,	NULL
was	NULL
not	NULL
altered	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
two	NULL
transactivators	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
Z-	NULL
and	NULL
R-responsive	NULL
regions	NULL
in	NULL
the	NULL
EA-D	NULL
promoter	NULL
.	NULL

To	NULL
define	NULL
the	NULL
Z-	NULL
and	NULL
R-responsive	NULL
region	NULL
(	NULL
s	NULL
)	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
,	NULL
we	NULL
created	NULL
a	NULL
series	NULL
of	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
pEA-CAT	NULL
plasmid	NULL
.	NULL

These	NULL
deletions	NULL
are	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
parent	NULL
pEA-CAT	NULL
plasmid	NULL
contains	NULL
EBV	NULL
nucleotides	NULL
79537	NULL
to	NULL
79898	NULL
(	NULL
-331	NULL
to	NULL
+1	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
RNA	NULL
start	NULL
site	NULL
.	NULL

Four	NULL
deletion	NULL
plasmids	NULL
were	NULL
constructed	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
which	NULL
delete	NULL
progressively	NULL
larger	NULL
fragments	NULL
of	NULL
the	NULL
upstream	NULL
5	NULL
'	NULL
promoter	NULL
sequences	NULL
.	NULL

The	NULL
smallest	NULL
construct	NULL
,	NULL
pEA-CAT	NULL
(	NULL
-62	NULL
to	NULL
+29	NULL
)	NULL
contains	NULL
only	NULL
62	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
cap	NULL
site	NULL
.	NULL

A	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
is	NULL
located	NULL
between	NULL
-57	NULL
and	NULL
-64	NULL
relative	NULL
to	NULL
the	NULL
start	NULL
site	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
the	NULL
Z	NULL
,	NULL
R	NULL
,	NULL
and	NULL
Z/R	NULL
transactivating	NULL
proteins	NULL
on	NULL
these	NULL
pEA-CAT	NULL
5	NULL
'	NULL
deletions	NULL
are	NULL
summarized	NULL
in	NULL
Tables	NULL
1	NULL
and	NULL
2	NULL
.	NULL

In	NULL
lymphoid	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
the	NULL
data	NULL
indicate	NULL
that	NULL
maximum	NULL
-	NULL
transactivation	NULL
of	NULL
the	NULL
parent	NULL
pEA-CAT	NULL
is	NULL
achieved	NULL
only	NULL
when	NULL
both	NULL
Z	NULL
and	NULL
R	NULL
are	NULL
present	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
could	NULL
be	NULL
significantly	NULL
increased	NULL
by	NULL
deleting	NULL
the	NULL
sequences	NULL
from	NULL
-331	NULL
to	NULL
-265	NULL
,	NULL
although	NULL
even	NULL
with	NULL
this	NULL
construct	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
together	NULL
was	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
Z	NULL
alone	NULL
(	NULL
85.3-fold	NULL
transactivation	NULL
versus	NULL
18.8-fold	NULL
)	NULL
.	NULL

A	NULL
progressive	NULL
loss	NULL
of	NULL
response	NULL
to	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
,	NULL
or	NULL
the	NULL
Z-plus-R	NULL
combination	NULL
,	NULL
occurred	NULL
as	NULL
5	NULL
'	NULL
3756	NULL
HOLLEY-GUTHRIE	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

TABLE	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
EBV-IE	NULL
transactivators	NULL
on	NULL
pEA-CAT	NULL
deletion	NULL
plasmids	NULL
in	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
Plasmi	NULL
Constitutive	NULL
Fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
``	NULL
asmid	NULL
folave	NULL
activity	NULL
pEBV-ZIE	NULL
pEBV-RIE	NULL
pEBV-RZ	NULL
pEA	NULL
(	NULL
-331/+1	NULL
)	NULL
-CAT	NULL
1.3	NULL
(	NULL
0.7-2.3	NULL
)	NULL
3.7	NULL
(	NULL
2.1-6.4	NULL
)	NULL
3.1	NULL
(	NULL
2.6-3.7	NULL
)	NULL
33.7	NULL
(	NULL
22.8-61.0	NULL
)	NULL
pEA	NULL
(	NULL
-265/+1	NULL
)	NULL
-CAT	NULL
0.7	NULL
(	NULL
0.6-1.0	NULL
)	NULL
18.8	NULL
(	NULL
4.0-31.2	NULL
)	NULL
4.0	NULL
(	NULL
2.2-5.3	NULL
)	NULL
85.3	NULL
(	NULL
50.5-119.5	NULL
)	NULL
pEA	NULL
(	NULL
-214/+29	NULL
)	NULL
-CAT	NULL
0.9	NULL
(	NULL
0.6-1.1	NULL
)	NULL
4.2	NULL
(	NULL
1.9-8.2	NULL
)	NULL
2.5	NULL
(	NULL
1.9-3.7	NULL
)	NULL
23.3	NULL
(	NULL
20.4-27.8	NULL
)	NULL
pEA	NULL
(	NULL
-79/+1	NULL
)	NULL
-CAT	NULL
2.0	NULL
(	NULL
1.3-2.4	NULL
)	NULL
1.6	NULL
(	NULL
0.5-2.4	NULL
)	NULL
3.4	NULL
(	NULL
1.2-4.5	NULL
)	NULL
4.9	NULL
(	NULL
4.4-5.8	NULL
)	NULL
pEA	NULL
(	NULL
-62/+29	NULL
)	NULL
-CAT	NULL
4.7	NULL
(	NULL
3.0-7.6	NULL
)	NULL
1.5	NULL
(	NULL
0.7-2.8	NULL
)	NULL
1.6	NULL
(	NULL
0.6-2.4	NULL
)	NULL
1.7	NULL
(	NULL
0.4-2.7	NULL
)	NULL
*	NULL
The	NULL
numbers	NULL
shown	NULL
represent	NULL
the	NULL
average	NULL
percent	NULL
acetylation	NULL
from	NULL
four	NULL
experiments	NULL
.	NULL

Ranges	NULL
are	NULL
given	NULL
in	NULL
parentheses	NULL
.	NULL

*	NULL
The	NULL
numbers	NULL
shown	NULL
represent	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
when	NULL
each	NULL
CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
either	NULL
pEBV-ZIE	NULL
,	NULL
pEBV-RIE	NULL
,	NULL
or	NULL
pEBV-RZ	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
activity	NULL
with	NULL
the	NULL
pHD1013	NULL
vector	NULL
.	NULL

Ranges	NULL
(	NULL
in	NULL
parentheses	NULL
)	NULL
are	NULL
those	NULL
from	NULL
three	NULL
experiments	NULL
for	NULL
pEBV-RIE	NULL
and	NULL
four	NULL
experiments	NULL
for	NULL
pEBV-ZIE	NULL
and	NULL
pEBV-RZ	NULL
.	NULL

sequences	NULL
between	NULL
-265	NULL
and	NULL
-62	NULL
were	NULL
deleted	NULL
,	NULL
although	NULL
the	NULL
region	NULL
located	NULL
between	NULL
-265	NULL
and	NULL
-214	NULL
appeared	NULL
to	NULL
play	NULL
the	NULL
greatest	NULL
role	NULL
in	NULL
the	NULL
total	NULL
transactivation	NULL
.	NULL

Neither	NULL
the	NULL
intact	NULL
pEA-CAT	NULL
plasmid	NULL
nor	NULL
any	NULL
of	NULL
the	NULL
5	NULL
'	NULL
deletion	NULL
mutations	NULL
were	NULL
significantly	NULL
transactivated	NULL
with	NULL
the	NULL
R-gene	NULL
product	NULL
alone	NULL
in	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
.	NULL

In	NULL
HeLa	NULL
cells	NULL
,	NULL
maximum	NULL
stimulation	NULL
of	NULL
the	NULL
parent	NULL
,	NULL
pEA-CAT	NULL
,	NULL
occurred	NULL
with	NULL
the	NULL
Z	NULL
transactivation	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
together	NULL
on	NULL
each	NULL
mutant	NULL
was	NULL
no	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
Z	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
a	NULL
significant	NULL
portion	NULL
of	NULL
the	NULL
Z	NULL
effect	NULL
in	NULL
HeLa	NULL
cells	NULL
was	NULL
lost	NULL
when	NULL
the	NULL
sequences	NULL
between	NULL
-265	NULL
and	NULL
-214	NULL
were	NULL
deleted	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
situation	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
total	NULL
Z	NULL
response	NULL
actually	NULL
was	NULL
increased	NULL
in	NULL
epithelial	NULL
cells	NULL
when	NULL
the	NULL
sequences	NULL
between	NULL
-214	NULL
and	NULL
-79	NULL
A	NULL
.	NULL

B	NULL
C	NULL
V	NULL
-	NULL
118	NULL
bp	NULL
-	NULL
72	NULL
bp	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Primer	NULL
extension	NULL
analysis	NULL
of	NULL
pEA-CAT	NULL
RNA	NULL
.	NULL

The	NULL
pEA-CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
either	NULL
the	NULL
pHD1013	NULL
vector	NULL
(	NULL
lane	NULL
B	NULL
)	NULL
or	NULL
the	NULL
Z/R	NULL
transactivating	NULL
plasmid	NULL
,	NULL
pEBV-RZ	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
.	NULL

RNA	NULL
(	NULL
50	NULL
pg	NULL
)	NULL
from	NULL
untransfected	NULL
Jurkat	NULL
cells	NULL
(	NULL
lane	NULL
A	NULL
)	NULL
or	NULL
pEA-CAT	NULL
transfected	NULL
cells	NULL
was	NULL
hybridized	NULL
overnight	NULL
with	NULL
a	NULL
y-*P-labeled	NULL
oligonucleotide	NULL
primer	NULL
homologous	NULL
to	NULL
CAT	NULL
gene	NULL
sequences	NULL
15	NULL
to	NULL
34	NULL
bp	NULL
downstream	NULL
of	NULL
the	NULL
ATG	NULL
codon	NULL
.	NULL

Primer	NULL
extension	NULL
(	NULL
18	NULL
)	NULL
was	NULL
performed	NULL
with	NULL
reverse	NULL
transcriptase	NULL
at	NULL
42Â°C	NULL
for	NULL
90	NULL
min	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
mRNA	NULL
start	NULL
site	NULL
mapped	NULL
at	NULL
EBV	NULL
sequence	NULL
79897	NULL
and	NULL
was	NULL
not	NULL
altered	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
two	NULL
transactivators	NULL
.	NULL

Cotransfection	NULL
with	NULL
the	NULL
R-plus-Z	NULL
transactivator	NULL
demonstrated	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
steady-state	NULL
level	NULL
of	NULL
EA-CAT	NULL
mRNA	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
arrow	NULL
.	NULL

were	NULL
deleted	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
,	NULL
the	NULL
17-bp	NULL
region	NULL
between	NULL
-79	NULL
and	NULL
-62	NULL
(	NULL
which	NULL
contains	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
)	NULL
also	NULL
contributed	NULL
to	NULL
Z	NULL
responsiveness	NULL
,	NULL
since	NULL
the	NULL
pEA	NULL
construct	NULL
(	NULL
-79	NULL
to	NULL
+1	NULL
)	NULL
was	NULL
13-fold	NULL
more	NULL
responsive	NULL
to	NULL
Z	NULL
than	NULL
the	NULL
pEA	NULL
construct	NULL
(	NULL
-62	NULL
to	NULL
+29	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
R	NULL
alone	NULL
in	NULL
HeLa	NULL
cells	NULL
was	NULL
too	NULL
small	NULL
to	NULL
be	NULL
accurately	NULL
mapped	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
in	NULL
Z	NULL
and	NULL
R	NULL
transactivation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
.	NULL

To	NULL
better	NULL
define	NULL
the	NULL
role	NULL
of	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
in	NULL
Z-	NULL
and	NULL
Z/R-induced	NULL
transactivation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
series	NULL
of	NULL
site-directed	NULL
mutants	NULL
of	NULL
the	NULL
EA-CAT	NULL
construct	NULL
by	NULL
using	NULL
in	NULL
vitro	NULL
mutagenesis	NULL
.	NULL

To	NULL
facilitate	NULL
these	NULL
studies	NULL
,	NULL
we	NULL
transferred	NULL
the	NULL
EA-D	NULL
promoter	NULL
sequences	NULL
and	NULL
CAT	NULL
gene	NULL
from	NULL
the	NULL
pEA-CAT	NULL
construct	NULL
into	NULL
a	NULL
Bluescript	NULL
M13	NULL
SK+	NULL
phagemid	NULL
vector	NULL
to	NULL
create	NULL
the	NULL
construct	NULL
pEA-BS-CAT	NULL
.	NULL

Using	NULL
the	NULL
method	NULL
of	NULL
Kunkel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
,	NULL
the	NULL
6	NULL
bp	NULL
defining	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
in	NULL
pEA-BS-CAT	NULL
was	NULL
specifically	NULL
altered	NULL
as	NULL
shown	NULL
in	NULL
Table	NULL
3	NULL
,	NULL
leaving	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
promoter	NULL
unchanged	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
since	NULL
analysis	NULL
of	NULL
the	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
suggested	NULL
that	NULL
sequences	NULL
further	NULL
upstream	NULL
from	NULL
the	NULL
potential	NULL
AP-1	NULL
site	NULL
may	NULL
also	NULL
contribute	NULL
to	NULL
Z/R	NULL
transactivation	NULL
,	NULL
three	NULL
other	NULL
site-directed	NULL
mutants	NULL
were	NULL
constructed	NULL
which	NULL
each	NULL
remove	NULL
potential	NULL
AP-l-like	NULL
binding	NULL
sites	NULL
lying	NULL
between	NULL
-197	NULL
and	NULL
-240	NULL
.	NULL

One	NULL
additional	NULL
mutant	NULL
,	NULL
which	NULL
alters	NULL
a	NULL
sequence	NULL
(	NULL
-185	NULL
to	NULL
-198	NULL
)	NULL
containing	NULL
a	NULL
10-of-14-bp	NULL
similarity	NULL
to	NULL
the	NULL
shared	NULL
R-response	NULL
sequence	NULL
region	NULL
of	NULL
the	NULL
DR	NULL
and	NULL
BMLF1	NULL
enhancers	NULL
(	NULL
1-3	NULL
,	NULL
12	NULL
)	NULL
was	NULL
also	NULL
constructed	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
the	NULL
Z	NULL
,	NULL
R	NULL
,	NULL
and	NULL
Z/R	NULL
transactivators	NULL
on	NULL
these	NULL
site-directed	NULL
mutants	NULL
are	NULL
shown	NULL
in	NULL
Tables	NULL
4	NULL
and	NULL
5	NULL
.	NULL

The	NULL
AP-1	NULL
site-directed	NULL
mutation	NULL
in	NULL
pEAAAPI-CAT	NULL
decreased	NULL
Z-induced	NULL
transactivation	NULL
in	NULL
HeLa	NULL
cells	NULL
by	NULL
more	NULL
than	NULL
20-fold	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
EA-D	NULL
regulation	NULL
in	NULL
epithelial	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
in	NULL
lymphoid	NULL
cells	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
,	NULL
the	NULL
AP-1	NULL
mutation	NULL
produced	NULL
little	NULL
TABLE	NULL
2	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
BZLFI1	NULL
transactivator	NULL
on	NULL
pEA-CAT	NULL
deletion	NULL
plasmids	NULL
in	NULL
the	NULL
HeLa	NULL
cell	NULL
line	NULL
Constitutive	NULL
Fold	NULL
increase	NULL
in	NULL
CAT	NULL
Plasmid	NULL
activity	NULL
``	NULL
activity	NULL
``	NULL
pEA	NULL
(	NULL
-331/+1	NULL
)	NULL
-CAT	NULL
0.7	NULL
(	NULL
0.7-0.7	NULL
)	NULL
65.0	NULL
(	NULL
33.0-96.5	NULL
)	NULL
pEA	NULL
(	NULL
-265/+1	NULL
)	NULL
-CAT	NULL
0.5	NULL
(	NULL
0.4-0.6	NULL
)	NULL
111.9	NULL
(	NULL
94.5-129.2	NULL
)	NULL
pEA	NULL
(	NULL
-214/+29	NULL
)	NULL
-CAT	NULL
0.7	NULL
(	NULL
0.5-0.9	NULL
)	NULL
2.5	NULL
(	NULL
1.0-4.0	NULL
)	NULL
pEA	NULL
(	NULL
-79/+1	NULL
)	NULL
-CAT	NULL
0.5	NULL
(	NULL
0.4-0.6	NULL
)	NULL
13.0	NULL
(	NULL
12.0-14.9	NULL
)	NULL
pEA	NULL
(	NULL
-62/+29	NULL
)	NULL
-CAT	NULL
0.5	NULL
(	NULL
0.4-0.5	NULL
)	NULL
1.1	NULL
(	NULL
0.6-1.5	NULL
)	NULL
``	NULL
The	NULL
numbers	NULL
shown	NULL
represent	NULL
the	NULL
percent	NULL
acetylation	NULL
produced	NULL
by	NULL
each	NULL
construct	NULL
and	NULL
are	NULL
derived	NULL
from	NULL
two	NULL
experiments	NULL
.	NULL

Ranges	NULL
are	NULL
given	NULL
in	NULL
parentheses	NULL
.	NULL

*	NULL
The	NULL
numbers	NULL
shown	NULL
represent	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
when	NULL
each	NULL
CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
pEBV-ZIE	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
activity	NULL
with	NULL
the	NULL
pHD1013	NULL
vector	NULL
.	NULL

Ranges	NULL
(	NULL
in	NULL
parentheses	NULL
)	NULL
are	NULL
results	NULL
of	NULL
two	NULL
experiments	NULL
.	NULL

Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
TABLE	NULL
3	NULL
.	NULL

Construction	NULL
of	NULL
in	NULL
vitro	NULL
site-directed	NULL
mutations	NULL
in	NULL
pEA-CAT	NULL
Altered	NULL
sequences	NULL
relative	NULL
Plasmid	NULL
to	NULL
mRNA	NULL
start	NULL
site	NULL
Mutations	NULL
pEAAAPI-CAT	NULL
-57	NULL
to	NULL
-63	NULL
TGACTCAÂ®-	NULL
TCAGCTG	NULL
pEAAZAI-CAT	NULL
-240	NULL
to	NULL
-246	NULL
TGGCTCG*	NULL
``	NULL
-	NULL
TCAGCTG	NULL
pEAAZB2-CAT	NULL
-230	NULL
to	NULL
-236	NULL
AACTGCTÂ®	NULL
-	NULL
ACAGCTG	NULL
pEAAZA3-CAT	NULL
-197	NULL
to	NULL
-203	NULL
TCACCCAÂ®	NULL
-	NULL
CAGCTGA	NULL
pEAAZB4-CAT	NULL
-190	NULL
to	NULL
-19	NULL
%	NULL
6	NULL
ACCAATGÂ®-	NULL
CAGCTGG	NULL
``	NULL
The	NULL
mutation	NULL
AAP	NULL
]	NULL
alters	NULL
the	NULL
perfect	NULL
consensus	NULL
AP-1	NULL
binding	NULL
site	NULL
located	NULL
between	NULL
-57	NULL
and	NULL
-63	NULL
.	NULL

Â®	NULL
Mutations	NULL
AZA1	NULL
,	NULL
AZB2	NULL
,	NULL
and	NULL
AZB3	NULL
each	NULL
alter	NULL
sequences	NULL
containing	NULL
a	NULL
4-0f-8-bp	NULL
similarity	NULL
to	NULL
the	NULL
consensus	NULL
AP-1	NULL
site	NULL
.	NULL

Â©	NULL
The	NULL
mutation	NULL
AZB4	NULL
alters	NULL
a	NULL
sequence	NULL
which	NULL
shares	NULL
a	NULL
10-of-14-bp	NULL
similarity	NULL
with	NULL
the	NULL
previously	NULL
described	NULL
shared	NULL
R-response	NULL
regions	NULL
in	NULL
the	NULL
EBV	NULL
DR	NULL
and	NULL
BMLF1	NULL
enhancers	NULL
(	NULL
2	NULL
,	NULL
3	NULL
,	NULL
12	NULL
)	NULL
.	NULL

effect	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
together	NULL
to	NULL
transactivate	NULL
the	NULL
EA-D	NULL
promoter	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
R	NULL
to	NULL
interact	NULL
synergistically	NULL
with	NULL
Z	NULL
in	NULL
lymphoid	NULL
cells	NULL
is	NULL
not	NULL
mediated	NULL
by	NULL
increased	NULL
Z	NULL
binding	NULL
to	NULL
the	NULL
consensus	NULL
AP-1	NULL
site	NULL
.	NULL

None	NULL
of	NULL
the	NULL
other	NULL
site-directed	NULL
mutants	NULL
significantly	NULL
affected	NULL
Z	NULL
or	NULL
Z-plus-R	NULL
transactivation	NULL
in	NULL
either	NULL
cell	NULL
type	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
demonstrated	NULL
in	NULL
these	NULL
studies	NULL
that	NULL
EA-D	NULL
(	NULL
BMRF1	NULL
)	NULL
promoter	NULL
regulation	NULL
by	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
IE	NULL
transactivators	NULL
is	NULL
cell	NULL
type	NULL
specific	NULL
and	NULL
appears	NULL
to	NULL
involve	NULL
different	NULL
mechanisms	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
,	NULL
the	NULL
Z	NULL
gene	NULL
product	NULL
efficiently	NULL
transactivates	NULL
the	NULL
promoter	NULL
for	NULL
the	NULL
EA-D	NULL
early	NULL
gene	NULL
,	NULL
whereas	NULL
effective	NULL
transactivation	NULL
of	NULL
the	NULL
same	NULL
promoter	NULL
in	NULL
lymphoid	NULL
cells	NULL
requires	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
R	NULL
transactivator	NULL
.	NULL

These	NULL
differences	NULL
in	NULL
transactivation	NULL
efficiency	NULL
correlate	NULL
with	NULL
different	NULL
mechanisms	NULL
of	NULL
transactivation	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
,	NULL
the	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
promoter	NULL
sequences	NULL
further	NULL
upstream	NULL
(	NULL
-214	NULL
to	NULL
-265	NULL
)	NULL
,	NULL
is	NULL
required	NULL
for	NULL
Z	NULL
response	NULL
.	NULL

In	NULL
lymphoid	NULL
cells	NULL
,	NULL
the	NULL
AP-1	NULL
site	NULL
is	NULL
dispensable	NULL
for	NULL
Z-plus-R	NULL
transactivation	NULL
,	NULL
although	NULL
the	NULL
upstream	NULL
regulatory	NULL
sequences	NULL
(	NULL
-214	NULL
to	NULL
-265	NULL
)	NULL
are	NULL
essential	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivators	NULL
to	NULL
synergistically	NULL
activate	NULL
the	NULL
EA-D	NULL
promoter	NULL
in	NULL
lymphoid	NULL
cells	NULL
appears	NULL
to	NULL
involve	NULL
a	NULL
mechanism	NULL
independent	NULL
of	NULL
Z	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
by	NULL
Z	NULL
and	NULL
R	NULL
is	NULL
distinct	NULL
from	NULL
that	NULL
of	NULL
other	NULL
EBV	NULL
promoters	NULL
previously	NULL
stud-ied	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
another	NULL
EBV	NULL
promoter	NULL
,	NULL
BMLF1	NULL
,	NULL
responds	NULL
to	NULL
the	NULL
R	NULL
transactivator	NULL
in	NULL
either	NULL
TABLE	NULL
4	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
BZLF	NULL
]	NULL
1	NULL
transactivator	NULL
on	NULL
pEA-CAT	NULL
site-directed	NULL
mutants	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
Fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
``	NULL
in	NULL
:	NULL
Plasmid	NULL
Jurkat	NULL
cells	NULL
HeLa	NULL
cells	NULL
pPEA-BS-CAT	NULL
2.3	NULL
(	NULL
1.4-3.2	NULL
)	NULL
156.9	NULL
(	NULL
60.6-326.0	NULL
)	NULL
pEAAAPL-CAT	NULL
0.4	NULL
(	NULL
0.3-0.5	NULL
)	NULL
7.0	NULL
(	NULL
5.3-7.6	NULL
)	NULL
pEAAZA1-CAT	NULL
2.8	NULL
(	NULL
0.9-4.6	NULL
)	NULL
71.5	NULL
(	NULL
47.8-95.4	NULL
)	NULL
pEAAZB2-CAT	NULL
3.0	NULL
(	NULL
2.0-4.0	NULL
)	NULL
68.1	NULL
(	NULL
36.9-117.5	NULL
)	NULL
pEAAZA3-CAT	NULL
2.0	NULL
(	NULL
2.0-2.1	NULL
)	NULL
46.3	NULL
(	NULL
41.6-52.1	NULL
)	NULL
pEAAZB4-CAT	NULL
1.8	NULL
(	NULL
1.1-2.6	NULL
)	NULL
71.4	NULL
(	NULL
49.2-93.5	NULL
)	NULL
*	NULL
The	NULL
numbers	NULL
shown	NULL
represent	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
when	NULL
each	NULL
CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
the	NULL
pEBV-ZIE	NULL
plasmid	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
activity	NULL
with	NULL
the	NULL
pHD1013	NULL
vector	NULL
.	NULL

Ranges	NULL
(	NULL
in	NULL
parentheses	NULL
)	NULL
are	NULL
those	NULL
from	NULL
two	NULL
experiments	NULL
with	NULL
Jurkat	NULL
ceils	NULL
and	NULL
three	NULL
experiments	NULL
with	NULL
HeLa	NULL
cells	NULL
.	NULL

CELL-SPECIFIC	NULL
REGULATION	NULL
OF	NULL
AN	NULL
EBV	NULL
PROMOTER	NULL
3757	NULL
TABLE	NULL
5	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
combined	NULL
BRLF1/BZLF1	NULL
transactivators	NULL
on	NULL
pEA-CAT	NULL
site-directed	NULL
mutants	NULL
in	NULL
Jurkat	NULL
cells	NULL
Fold	NULL
increase	NULL
in	NULL
CAT	NULL
Plasmid	NULL
activity	NULL
``	NULL
pEA-BS-CAT	NULL
eer	NULL
reer	NULL
rece	NULL
s	NULL
ece	NULL
s	NULL
ees	NULL
43.1	NULL
(	NULL
30.8-52.0	NULL
)	NULL
pEAAAPI-CAT	NULL
rere	NULL
seas	NULL
rea	NULL
50.3	NULL
(	NULL
36.8-74.8	NULL
)	NULL
pEAAZAL-CAT	NULL
06	NULL
rre	NULL
rer	NULL
errr	NULL
sra	NULL
es	NULL
110.3	NULL
(	NULL
52.5-213.6	NULL
)	NULL
pPEAAZB2-CAT	NULL
vre	NULL
evere	NULL
veces	NULL
eek	NULL
76.9	NULL
(	NULL
22.8-163.2	NULL
)	NULL
pEAAZA3-CAT	NULL
602000060	NULL
erve	NULL
reserve	NULL
ence	NULL
eek	NULL
99.3	NULL
(	NULL
61.4-138.0	NULL
)	NULL
f	NULL
)	NULL
)	NULL
59	NULL
VV	NULL
A	NULL
:	NULL
E	NULL
of	NULL
.	NULL

v	NULL
oe	NULL
91.1	NULL
(	NULL
37.2-197.6	NULL
)	NULL
``	NULL
The	NULL
numbers	NULL
shown	NULL
represent	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
when	NULL
each	NULL
CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
the	NULL
pEBV-RZ	NULL
plasmid	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
activity	NULL
with	NULL
the	NULL
pHD1013	NULL
vector	NULL
.	NULL

Ranges	NULL
are	NULL
those	NULL
from	NULL
two	NULL
experiments	NULL
.	NULL

EBV-positive	NULL
or	NULL
EBV-negative	NULL
lymphoid	NULL
and	NULL
epithelial	NULL
cells	NULL
,	NULL
and	NULL
mapped	NULL
the	NULL
R-response	NULL
region	NULL
in	NULL
this	NULL
promoter	NULL
to	NULL
a	NULL
140-bp	NULL
enhancer	NULL
element	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Several	NULL
investigators	NULL
have	NULL
reported	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
R	NULL
,	NULL
the	NULL
BMLF1	NULL
promoter	NULL
can	NULL
be	NULL
activated	NULL
(	NULL
although	NULL
to	NULL
a	NULL
much	NULL
lesser	NULL
extent	NULL
)	NULL
by	NULL
the	NULL
Z	NULL
transactivator	NULL
,	NULL
and	NULL
they	NULL
have	NULL
mapped	NULL
the	NULL
Z-response	NULL
region	NULL
to	NULL
an	NULL
AP-1	NULL
site	NULL
(	NULL
1	NULL
,	NULL
12	NULL
,	NULL
30	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Our	NULL
studies	NULL
suggest	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
BMLF1	NULL
and	NULL
BMRFI1	NULL
(	NULL
EA-D	NULL
)	NULL
promoters	NULL
by	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
transactivators	NULL
is	NULL
clearly	NULL
different	NULL
.	NULL

The	NULL
BMLF1	NULL
promoter	NULL
is	NULL
primarily	NULL
R	NULL
re-sponsive	NULL
,	NULL
and	NULL
the	NULL
effect	NULL
of	NULL
R	NULL
and	NULL
Z	NULL
together	NULL
is	NULL
no	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
R	NULL
alone	NULL
(	NULL
at	NULL
least	NULL
when	NULL
levels	NULL
of	NULL
R	NULL
and	NULL
Z	NULL
are	NULL
not	NULL
limiting	NULL
)	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
tissue	NULL
specificity	NULL
in	NULL
the	NULL
effects	NULL
of	NULL
R	NULL
or	NULL
Z	NULL
on	NULL
BMLFl	NULL
promoter	NULL
activity	NULL
has	NULL
been	NULL
observed	NULL
(	NULL
1	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Unlike	NULL
the	NULL
case	NULL
with	NULL
BMRF1	NULL
,	NULL
in	NULL
the	NULL
BMLF1	NULL
promoter	NULL
the	NULL
R-responsive	NULL
and	NULL
Z-responsive	NULL
regions	NULL
of	NULL
the	NULL
promoter	NULL
clearly	NULL
map	NULL
to	NULL
separate	NULL
regions	NULL
.	NULL

Studies	NULL
involving	NULL
the	NULL
EBV	NULL
divergent	NULL
promoter	NULL
and	NULL
BHRF1	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivators	NULL
are	NULL
both	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
this	NULL
complex	NULL
element	NULL
.	NULL

The	NULL
R-responsive	NULL
region	NULL
of	NULL
this	NULL
promoter	NULL
element	NULL
can	NULL
be	NULL
clearly	NULL
mapped	NULL
to	NULL
an	NULL
enhancer	NULL
region	NULL
which	NULL
contains	NULL
a	NULL
14-bp	NULL
sequence	NULL
similar	NULL
to	NULL
a	NULL
sequence	NULL
in	NULL
the	NULL
R-responsive	NULL
enhancer	NULL
of	NULL
the	NULL
BMLF1	NULL
promoter	NULL
(	NULL
1-3	NULL
,	NULL
12	NULL
)	NULL
.	NULL

The	NULL
Z	NULL
transactivator	NULL
also	NULL
activates	NULL
the	NULL
BHLF	NULL
]	NULL
1	NULL
promoter	NULL
.	NULL

Lieberman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
regulation	NULL
of	NULL
the	NULL
BHLF1	NULL
promoter	NULL
by	NULL
Z	NULL
is	NULL
tissue	NULL
specific	NULL
,	NULL
with	NULL
the	NULL
response	NULL
region	NULL
to	NULL
Z	NULL
being	NULL
located	NULL
in	NULL
sequences	NULL
between	NULL
-7	NULL
and	NULL
-155	NULL
in	NULL
Vero	NULL
cells	NULL
but	NULL
localized	NULL
within	NULL
sequences	NULL
further	NULL
upstream	NULL
in	NULL
EBV-positive	NULL
lymphoid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
Z	NULL
effect	NULL
observed	NULL
in	NULL
EBV-positive	NULL
cells	NULL
was	NULL
actually	NULL
mediated	NULL
by	NULL
the	NULL
R	NULL
transactivator	NULL
and	NULL
did	NULL
not	NULL
represent	NULL
true	NULL
tissue-specific	NULL
differences	NULL
in	NULL
Z	NULL
response	NULL
elements	NULL
.	NULL

Although	NULL
the	NULL
DR	NULL
enhancer	NULL
region	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
R	NULL
alone	NULL
and	NULL
not	NULL
by	NULL
Z	NULL
alone	NULL
,	NULL
Cox	NULL
et	NULL
al	NULL
.	NULL

have	NULL
recently	NULL
reported	NULL
that	NULL
the	NULL
combination	NULL
of	NULL
R	NULL
and	NULL
Z	NULL
activates	NULL
the	NULL
DR	NULL
enhancer	NULL
synergistically	NULL
(	NULL
5	NULL
)	NULL
.	NULL

This	NULL
synergistic	NULL
effect	NULL
of	NULL
the	NULL
Z-plus-R	NULL
combination	NULL
on	NULL
the	NULL
DR	NULL
enhancer	NULL
element	NULL
is	NULL
different	NULL
from	NULL
the	NULL
EA-D	NULL
promoter	NULL
effect	NULL
described	NULL
here	NULL
in	NULL
several	NULL
ways	NULL
.	NULL

The	NULL
EA-D	NULL
effect	NULL
is	NULL
tissue	NULL
specific	NULL
,	NULL
with	NULL
synergy	NULL
occurring	NULL
in	NULL
lymphoid	NULL
cells	NULL
but	NULL
not	NULL
epithelial	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
EA-D	NULL
promoter	NULL
appears	NULL
to	NULL
be	NULL
primarily	NULL
Z	NULL
responsive	NULL
in	NULL
epithelial	NULL
cells	NULL
,	NULL
at	NULL
least	NULL
when	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
transactivators	NULL
are	NULL
tested	NULL
separately	NULL
,	NULL
the	NULL
DR	NULL
enhancer	NULL
is	NULL
primarily	NULL
R	NULL
responsive	NULL
(	NULL
2	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
DR	NULL
enhancer	NULL
has	NULL
a	NULL
clearly	NULL
mapped	NULL
R	NULL
response	NULL
region	NULL
which	NULL
contains	NULL
the	NULL
14-bp	NULL
element	NULL
CCGTGGACAAT	NULL
GTC	NULL
(	NULL
similar	NULL
to	NULL
the	NULL
R	NULL
response	NULL
element	NULL
in	NULL
the	NULL
BMLFI	NULL
promoter	NULL
)	NULL
and	NULL
can	NULL
transfer	NULL
R	NULL
responsiveness	NULL
to	NULL
heterologous	NULL
promoters	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
R	NULL
alone	NULL
on	NULL
the	NULL
EA-D	NULL
promoter	NULL
is	NULL
minimal	NULL
and	NULL
does	NULL
not	NULL
map	NULL
to	NULL
a	NULL
single	NULL
region	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
EA-D	NULL
promoter	NULL
does	NULL
con	NULL
3758	NULL
HOLLEY-GUTHRIE	NULL
ET	NULL
AL	NULL
.	NULL

tain	NULL
the	NULL
sequence	NULL
GCCTGACCAATGTC	NULL
(	NULL
from	NULL
-185	NULL
to	NULL
-198	NULL
)	NULL
,	NULL
which	NULL
has	NULL
a	NULL
10-of-14-bp	NULL
similarity	NULL
to	NULL
the	NULL
14-bp	NULL
element	NULL
shared	NULL
by	NULL
the	NULL
BMLF1	NULL
and	NULL
DR	NULL
enhancers	NULL
.	NULL

However	NULL
,	NULL
the	NULL
site-directed	NULL
mutant	NULL
EAAZB4-CAT	NULL
,	NULL
which	NULL
mutates	NULL
6	NULL
bp	NULL
of	NULL
the	NULL
above	NULL
sequence	NULL
,	NULL
continues	NULL
to	NULL
response	NULL
to	NULL
the	NULL
Z-plus-R	NULL
combination	NULL
.	NULL

These	NULL
data	NULL
together	NULL
suggest	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
and	NULL
R	NULL
to	NULL
act	NULL
synergistically	NULL
upon	NULL
the	NULL
EA-D	NULL
promoter	NULL
and	NULL
DR	NULL
enhancer	NULL
elements	NULL
may	NULL
occur	NULL
through	NULL
different	NULL
mechanisms	NULL
.	NULL

It	NULL
is	NULL
not	NULL
clear	NULL
why	NULL
the	NULL
Z	NULL
effect	NULL
in	NULL
epithelial	NULL
cells	NULL
is	NULL
greater	NULL
with	NULL
the	NULL
pEA	NULL
(	NULL
-79/+1	NULL
)	NULL
construct	NULL
than	NULL
with	NULL
the	NULL
pEA	NULL
(	NULL
-214/	NULL
+29	NULL
)	NULL
construct	NULL
.	NULL

There	NULL
may	NULL
be	NULL
two	NULL
separate	NULL
Z	NULL
response	NULL
elements	NULL
,	NULL
one	NULL
located	NULL
between	NULL
-214	NULL
and	NULL
-264	NULL
and	NULL
the	NULL
other	NULL
located	NULL
between	NULL
-79	NULL
and	NULL
-62	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
the	NULL
BstEII-BstXI	NULL
fragment	NULL
(	NULL
-79	NULL
to	NULL
-264	NULL
)	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
transfer	NULL
Z	NULL
or	NULL
Z/R	NULL
responsiveness	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
early	NULL
promoter	NULL
in	NULL
pA1lOCAT	NULL
(	NULL
21	NULL
)	NULL
(	NULL
E.	NULL
Guthrie	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
results	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
both	NULL
the	NULL
upstream	NULL
and	NULL
downstream	NULL
response	NULL
elements	NULL
may	NULL
be	NULL
required	NULL
for	NULL
maximal	NULL
transactivation	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
to	NULL
transactivate	NULL
the	NULL
downstream	NULL
response	NULL
element	NULL
may	NULL
be	NULL
inhibited	NULL
by	NULL
sequences	NULL
between	NULL
-79	NULL
and	NULL
-214	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
BHLF1	NULL
promoter	NULL
sequences	NULL
located	NULL
between	NULL
-155	NULL
and	NULL
-417	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
exert	NULL
a	NULL
similar	NULL
negative	NULL
effect	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
to	NULL
transactivate	NULL
this	NULL
promoter	NULL
in	NULL
Vero	NULL
cells	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
increased	NULL
length	NULL
of	NULL
RNA	NULL
leader	NULL
sequences	NULL
in	NULL
the	NULL
-214/+29	NULL
and	NULL
-62/+29	NULL
constructs	NULL
may	NULL
inhibit	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
.	NULL

In	NULL
either	NULL
case	NULL
,	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
located	NULL
between	NULL
-57	NULL
and	NULL
-64	NULL
)	NULL
for	NULL
Z	NULL
transactivation	NULL
in	NULL
epithelial	NULL
cells	NULL
was	NULL
confirmed	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
AP-1	NULL
site	NULL
.	NULL

Exactly	NULL
why	NULL
the	NULL
Z	NULL
protein	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
activate	NULL
the	NULL
R	NULL
promoter	NULL
in	NULL
epithelial	NULL
cells	NULL
,	NULL
yet	NULL
both	NULL
the	NULL
Z	NULL
and	NULL
R	NULL
proteins	NULL
are	NULL
required	NULL
for	NULL
maximum	NULL
activation	NULL
of	NULL
lymphoid	NULL
cells	NULL
,	NULL
is	NULL
still	NULL
speculative	NULL
.	NULL

Perhaps	NULL
there	NULL
is	NULL
a	NULL
cellular	NULL
factor	NULL
expressed	NULL
in	NULL
epithelial	NULL
cells	NULL
that	NULL
replaces	NULL
the	NULL
function	NULL
of	NULL
the	NULL
R	NULL
protein	NULL
.	NULL

If	NULL
so	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
this	NULL
hypothetical	NULL
epithelial-cell	NULL
factor	NULL
must	NULL
be	NULL
different	NULL
from	NULL
the	NULL
mechanism	NULL
of	NULL
R	NULL
,	NULL
since	NULL
the	NULL
AP-1	NULL
site	NULL
is	NULL
dispensable	NULL
for	NULL
the	NULL
Z-plus-R	NULL
interaction	NULL
,	NULL
but	NULL
not	NULL
when	NULL
Z	NULL
alone	NULL
is	NULL
used	NULL
in	NULL
epithelial	NULL
cells	NULL
.	NULL

There	NULL
may	NULL
be	NULL
a	NULL
factor	NULL
present	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
but	NULL
lacking	NULL
in	NULL
epithelial	NULL
cells	NULL
,	NULL
that	NULL
inhibits	NULL
efficient	NULL
binding	NULL
of	NULL
Z	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
.	NULL

In	NULL
this	NULL
case	NULL
the	NULL
helper	NULL
role	NULL
of	NULL
R	NULL
in	NULL
lymphoid	NULL
cells	NULL
might	NULL
involve	NULL
binding	NULL
by	NULL
Z	NULL
to	NULL
alternative	NULL
upstream	NULL
binding	NULL
sites	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
plus	NULL
R	NULL
in	NULL
lymphoid	NULL
cells	NULL
might	NULL
involve	NULL
direct	NULL
EA-D	NULL
binding	NULL
by	NULL
the	NULL
R	NULL
protein	NULL
(	NULL
with	NULL
Z	NULL
providing	NULL
a	NULL
helper	NULL
function	NULL
in	NULL
this	NULL
case	NULL
)	NULL
.	NULL

A	NULL
particularly	NULL
interesting	NULL
possibility	NULL
is	NULL
that	NULL
Z	NULL
and	NULL
R	NULL
might	NULL
act	NULL
synergistically	NULL
through	NULL
protein-protein	NULL
interactions	NULL
.	NULL

Distinguishing	NULL
between	NULL
these	NULL
possibilities	NULL
will	NULL
require	NULL
further	NULL
protein-DNA	NULL
binding	NULL
stud-ies	NULL
.	NULL

The	NULL
findings	NULL
presented	NULL
here	NULL
with	NULL
Jurkat	NULL
and	NULL
HeLa	NULL
cells	NULL
do	NULL
not	NULL
necessarily	NULL
correlate	NULL
with	NULL
the	NULL
regulation	NULL
of	NULL
EBV	NULL
infection	NULL
in	NULL
vivo	NULL
,	NULL
since	NULL
neither	NULL
of	NULL
these	NULL
cell	NULL
types	NULL
can	NULL
actually	NULL
be	NULL
infected	NULL
by	NULL
EBV	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
differences	NULL
observed	NULL
in	NULL
EA-D	NULL
promoter	NULL
regulation	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
are	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
the	NULL
degree	NULL
of	NULL
cell	NULL
differentiation	NULL
(	NULL
since	NULL
EBV	NULL
tends	NULL
to	NULL
be	NULL
more	NULL
productive	NULL
in	NULL
more	NULL
differentiated	NULL
cells	NULL
)	NULL
rather	NULL
than	NULL
to	NULL
tissue-specific	NULL
differences	NULL
.	NULL

Never-theless	NULL
,	NULL
these	NULL
findings	NULL
may	NULL
well	NULL
have	NULL
biological	NULL
relevance	NULL
in	NULL
EBV	NULL
infection	NULL
.	NULL

The	NULL
tendency	NULL
for	NULL
EBV	NULL
infection	NULL
to	NULL
remain	NULL
latent	NULL
in	NULL
lymphoid	NULL
cells	NULL
may	NULL
relate	NULL
to	NULL
the	NULL
requirement	NULL
in	NULL
this	NULL
cell	NULL
type	NULL
for	NULL
both	NULL
transactivating	NULL
proteins	NULL
,	NULL
Z	NULL
and	NULL
R	NULL
,	NULL
to	NULL
be	NULL
expressed	NULL
if	NULL
transactivation	NULL
of	NULL
certain	NULL
crucial	NULL
promoters	NULL
such	NULL
as	NULL
EA-D	NULL
and	NULL
the	NULL
DR	NULL
enhancer	NULL
element	NULL
is	NULL
to	NULL
occur	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
alone	NULL
to	NULL
activate	NULL
certain	NULL
promoters	NULL
J.	NULL
Viror	NULL
.	NULL

in	NULL
epithelial	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
lymphoid	NULL
cells	NULL
,	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
relative	NULL
permissiveness	NULL
of	NULL
this	NULL
cell	NULL
type	NULL
for	NULL
productive	NULL
viral	NULL
infection	NULL
.	NULL

The	NULL
requirement	NULL
for	NULL
R	NULL
transactivation	NULL
(	NULL
in	NULL
addition	NULL
to	NULL
Z	NULL
)	NULL
for	NULL
activation	NULL
of	NULL
certain	NULL
promoters	NULL
in	NULL
lymphoid	NULL
cells	NULL
suggests	NULL
that	NULL
R	NULL
function	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
crucial	NULL
in	NULL
the	NULL
disruption	NULL
of	NULL
viral	NULL
latency	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
whether	NULL
the	NULL
R	NULL
transactivating	NULL
function	NULL
is	NULL
also	NULL
required	NULL
for	NULL
productive	NULL
infection	NULL
of	NULL
epithelial	NULL
cells	NULL
remains	NULL
to	NULL
be	NULL
deter-mined	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
K08-CA01229-03	NULL
,	NULL
5-PO1-CA19014-12	NULL
,	NULL
and	NULL
1-UO1-AI256868-01	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

We	NULL
thank	NULL
Michele	NULL
Davis	NULL
and	NULL
Eng-Shang	NULL
Huang	NULL
for	NULL
use	NULL
of	NULL
the	NULL
pHD1013	NULL
vector	NULL
;	NULL
Bruce	NULL
Howard	NULL
for	NULL
RSV-CAT	NULL
and	NULL
pA10CAT	NULL
;	NULL
the	NULL
late	NULL
George	NULL
Khoury	NULL
for	NULL
pCAT3M	NULL
;	NULL
Gloria	NULL
Majette	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
and	NULL
Al	NULL
Baldwin	NULL
,	NULL
Nancy	NULL
Raab-Traub	NULL
,	NULL
and	NULL
Joseph	NULL
Pagano	NULL
for	NULL
reviewing	NULL
the	NULL
manuscript	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Buisson	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
M.	NULL
C.	NULL
Trescol-Biemont	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
early	NULL
protein	NULL
EB2	NULL
is	NULL
a	NULL
posttranscriptional	NULL
activator	NULL
expressed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
EBV	NULL
transcription	NULL
factors	NULL
EB1	NULL
and	NULL
R.	NULL
J.	NULL
Virol	NULL
.	NULL

63:5276-5284	NULL
.	NULL

2	NULL
.	NULL

Chavrier	NULL
,	NULL
P.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
A.	NULL
Chevallier-Greco	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
early	NULL
promoter	NULL
DR	NULL
contains	NULL
a	NULL
cis-acting	NULL
element	NULL
responsive	NULL
to	NULL
the	NULL
EBV	NULL
transactivator	NULL
EB1	NULL
and	NULL
an	NULL
enhancer	NULL
with	NULL
constitutive	NULL
and	NULL
inducible	NULL
activities	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:607-614	NULL
.	NULL

3	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
DR	NULL
enhancer	NULL
contains	NULL
two	NULL
functionally	NULL
different	NULL
domains	NULL
:	NULL
domain	NULL
A	NULL
is	NULL
constitutive	NULL
and	NULL
cell	NULL
specific	NULL
,	NULL
domain	NULL
B	NULL
is	NULL
transactivated	NULL
by	NULL
the	NULL
EBV	NULL
early	NULL
protein	NULL
R.	NULL
J.	NULL
Virol	NULL
.	NULL

63:615-623	NULL
.	NULL

4	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Chavrier	NULL
,	NULL
C.	NULL
Mosnier	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1986	NULL
.	NULL

Both	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-encoded	NULL
frans-activating	NULL
factors	NULL
,	NULL
EBl	NULL
and	NULL
EB2	NULL
,	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
an	NULL
EBV	NULL
early	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:3243-3249	NULL
.	NULL

5	NULL
.	NULL

Cox	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
J.	NULL
Leahy	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hardwick	NULL
.	NULL

1990	NULL
.	NULL

An	NULL
enhancer	NULL
within	NULL
the	NULL
divergent	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
responds	NULL
synergistically	NULL
to	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64	NULL
:	NULL
313-321	NULL
.	NULL

6	NULL
.	NULL

Dambaugh	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Hennessy	NULL
,	NULL
S.	NULL
Fennewald	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
virus	NULL
genome	NULL
and	NULL
its	NULL
expression	NULL
in	NULL
latent	NULL
expression	NULL
,	NULL
p.	NULL
13-45	NULL
.	NULL

In	NULL
M.	NULL
Epstein	NULL
and	NULL
B.	NULL
Achong	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

7	NULL
.	NULL

Farrell	NULL
,	NULL
P.	NULL
,	NULL
D.	NULL
Rowe	NULL
,	NULL
C.	NULL
Rooney	NULL
,	NULL
and	NULL
J.	NULL
T.	NULL
Kouzarides	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
frans-activator	NULL
specifically	NULL
binds	NULL
to	NULL
consensus	NULL
AP-1	NULL
site	NULL
and	NULL
is	NULL
related	NULL
to	NULL
c-fos	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:127-132	NULL
.	NULL

8	NULL
.	NULL

Gilman	NULL
,	NULL
M.	NULL
1988	NULL
.	NULL

Preparation	NULL
of	NULL
cytoplasmic	NULL
RNA	NULL
from	NULL
tissue	NULL
culture	NULL
cells	NULL
,	NULL
p.	NULL
4.1.2-4.1.6	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

9	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

10	NULL
.	NULL

Grogan	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
Jenson	NULL
,	NULL
J.	NULL
Countryman	NULL
,	NULL
L.	NULL
Heston	NULL
,	NULL
L.	NULL
Gradovile	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1987	NULL
.	NULL

Transfection	NULL
of	NULL
a	NULL
rearranged	NULL
viral	NULL
DNA	NULL
fragment	NULL
,	NULL
WZhet	NULL
,	NULL
stably	NULL
converts	NULL
latent	NULL
Epstein-Barr	NULL
viral	NULL
infection	NULL
to	NULL
productive	NULL
infection	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
$	NULL
4:1332-1336	NULL
.	NULL

11	NULL
.	NULL

Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
Lieberman	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
new	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
,	NULL
R	NULL
,	NULL
induces	NULL
expression	NULL
of	NULL
a	NULL
cytoplasmic	NULL
early	NULL
antigen	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:2274-2284	NULL
.	NULL

12	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
E.	NULL
C.	NULL
Mar	NULL
,	NULL
and	NULL
M.	NULL
Smith	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
BMLF	NULL
]	NULL
promoter	NULL
contains	NULL
an	NULL
enhancer	NULL
element	NULL
that	NULL
is	NULL
responsive	NULL
to	NULL
the	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
transacti-	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23.	NULL
vators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3878-3883	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Kamine	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
J.	NULL
C.	NULL
Lin	NULL
,	NULL
E.	NULL
C.	NULL
Mar	NULL
,	NULL
and	NULL
J.	NULL
Pagano	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
BZLF1	NULL
immediate-early	NULL
gene	NULL
product	NULL
differentially	NULL
affects	NULL
latent	NULL
versus	NULL
productive	NULL
EBV	NULL
promoters	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1729-1736	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Kamine	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
E.	NULL
C.	NULL
Mar	NULL
,	NULL
J.	NULL
C.	NULL
Lin	NULL
,	NULL
D.	NULL
Markovitz	NULL
,	NULL
and	NULL
J.	NULL
Pagano	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
immediate-early	NULL
gene	NULL
product	NULL
,	NULL
BMLF1	NULL
,	NULL
acts	NULL
in	NULL
frans	NULL
by	NULL
a	NULL
posttranscriptional	NULL
mechanism	NULL
which	NULL
is	NULL
reporter	NULL
gene	NULL
depen-dent	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3870-3877	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Kamine	NULL
,	NULL
D.	NULL
Markovitz	NULL
,	NULL
R.	NULL
Fenrick	NULL
,	NULL
and	NULL
J.	NULL
Pagano	NULL
.	NULL

1988	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus	NULL
immediate-early	NULL
gene	NULL
product	NULL
trans-activates	NULL
gene	NULL
expression	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
:	NULL
1652-1656	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
C.	NULL
Lin	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pagano	NULL
.	NULL

1987	NULL
.	NULL

Regulation	NULL
of	NULL
EBV	NULL
promoters	NULL
,	NULL
p.	NULL
163-168	NULL
.	NULL

In	NULL
P.	NULL
Levine	NULL
,	NULL
D.	NULL
Ablashi	NULL
,	NULL
N.	NULL
Nonoyama	NULL
,	NULL
G.	NULL
Pearson	NULL
,	NULL
and	NULL
R.	NULL
Glaser	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
human	NULL
disease	NULL
.	NULL

Humana	NULL
Press	NULL
,	NULL
Clifton	NULL
,	NULL
N.J.	NULL
Kikuta	NULL
,	NULL
H.	NULL
,	NULL
Y.	NULL
Taguchi	NULL
,	NULL
K.	NULL
Tomizawa	NULL
,	NULL
K.	NULL
Kojima	NULL
,	NULL
N.	NULL
Kawa-mura	NULL
,	NULL
A.	NULL
Ishizaka	NULL
,	NULL
Y.	NULL
Sakiyama	NULL
,	NULL
S.	NULL
Matsumoto	NULL
,	NULL
S.	NULL
Imai	NULL
,	NULL
T.	NULL
Kinoshita	NULL
,	NULL
S.	NULL
Koizumi	NULL
,	NULL
T.	NULL
Osato	NULL
,	NULL
I.	NULL
Kobayashi	NULL
,	NULL
I.	NULL
Hamada	NULL
,	NULL
and	NULL
K.	NULL
Hirai	NULL
.	NULL

1988	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
genome-positive	NULL
T	NULL
lympho-cytes	NULL
in	NULL
a	NULL
boy	NULL
with	NULL
chronic	NULL
active	NULL
EBV	NULL
infection	NULL
associated	NULL
with	NULL
Kawasaki-like	NULL
disease	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
333:455-457	NULL
.	NULL

Kingston	NULL
,	NULL
R.	NULL
E.	NULL
1987	NULL
.	NULL

Primer	NULL
extension	NULL
,	NULL
p.	NULL
4.8.1-4.8.3	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Kunkel	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

1985	NULL
.	NULL

Rapid	NULL
and	NULL
efficient	NULL
site-specific	NULL
mutagenesis	NULL
without	NULL
phenotypic	NULL
selection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:488-492	NULL
.	NULL

Kunkel	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
J.	NULL
D.	NULL
Roberts	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Zakour	NULL
.	NULL

1987	NULL
.	NULL

Rapid	NULL
and	NULL
efficient	NULL
site-specific	NULL
mutagenesis	NULL
without	NULL
phenotypic	NULL
selection	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

154:367-382	NULL
.	NULL

Laimins	NULL
,	NULL
L.	NULL
,	NULL
P.	NULL
Gruss	NULL
,	NULL
R.	NULL
Pozzatti	NULL
,	NULL
and	NULL
G.	NULL
Khoury	NULL
.	NULL

1984	NULL
.	NULL

Characterization	NULL
of	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
Moloney	NULL
murine	NULL
sarcoma	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

49:183-189	NULL
.	NULL

Li	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
B.	NULL
S.	NULL
Zhou	NULL
,	NULL
G.	NULL
E.	NULL
Dutschman	NULL
,	NULL
S.	NULL
P.	NULL
Grill	NULL
,	NULL
R.	NULL
S.	NULL
Tan	NULL
,	NULL
and	NULL
Y.	NULL
C.	NULL
Chen	NULL
.	NULL

1987	NULL
.	NULL

Association	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
antigen	NULL
diffuse	NULL
component	NULL
and	NULL
virus-specified	NULL
DNA	NULL
polymerase	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:2947-2949	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1989	NULL
.	NULL

Responsiveness	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
NotI	NULL
repeat	NULL
promoter	NULL
to	NULL
the	NULL
Z	NULL
transactivator	NULL
is	NULL
mediated	NULL
in	NULL
a	NULL
cell-type	NULL
specific	NULL
manner	NULL
by	NULL
two	NULL
independent	NULL
signal	NULL
regions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3040-3050	NULL
.	NULL

CELL-SPECIFIC	NULL
REGULATION	NULL
OF	NULL
AN	NULL
EBV	NULL
PROMOTER	NULL
24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

3759	NULL
Lieberman	NULL
,	NULL
P.	NULL
,	NULL
P.	NULL
O'Hare	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1986	NULL
.	NULL

Promiscuous	NULL
transactivation	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
an	NULL
Epstein-Barr	NULL
virus-encoded	NULL
early	NULL
nuclear	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

60:140-148	NULL
.	NULL

Manet	NULL
,	NULL
E.	NULL
H.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
M.	NULL
C.	NULL
Trescol-Biemont	NULL
,	NULL
N.	NULL
Moreno	NULL
,	NULL
P.	NULL
Chambard	NULL
,	NULL
J.	NULL
F.	NULL
Giot	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
bicistronic	NULL
mRNAs	NULL
generated	NULL
by	NULL
facultative	NULL
splicing	NULL
code	NULL
for	NULL
two	NULL
transcriptional	NULL
frans-activators	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1819-1826	NULL
.	NULL

Marschall	NULL
,	NULL
M.	NULL
,	NULL
U.	NULL
Leser	NULL
,	NULL
R.	NULL
Seibl	NULL
,	NULL
and	NULL
H.	NULL
S.	NULL
Wolf	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
proteins	NULL
encoded	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
trans-activator	NULL
genes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:938-942	NULL
.	NULL

McKnight	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
R.	NULL
Kingsbury	NULL
.	NULL

1982	NULL
.	NULL

Transcription	NULL
control	NULL
signals	NULL
of	NULL
a	NULL
eukaryotic	NULL
protein-coding	NULL
gene	NULL
.	NULL

Science	NULL
217	NULL
:	NULL
316-324	NULL
.	NULL

Miller	NULL
,	NULL
G.	NULL
1985	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
,	NULL
p.	NULL
563-590	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
,	NULL
N.	NULL
Taylor	NULL
,	NULL
J.	NULL
Countryman	NULL
,	NULL
H.	NULL
Jenson	NULL
,	NULL
J.	NULL
Kolman	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1988	NULL
.	NULL

Genome	NULL
rearrangements	NULL
activate	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
whose	NULL
product	NULL
disrupts	NULL
latency	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:9801-9805	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
D.	NULL
T.	NULL
Rowe	NULL
,	NULL
T.	NULL
Ragot	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
spliced	NULL
BZLF1	NULL
gene	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
transactivates	NULL
an	NULL
early	NULL
EBV	NULL
promoter	NULL
and	NULL
induces	NULL
the	NULL
virus	NULL
productive	NULL
cycle	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3109-3116	NULL
.	NULL

Shimizu	NULL
,	NULL
N.	NULL
,	NULL
S.	NULL
Sakuma	NULL
,	NULL
Y.	NULL
Ono	NULL
,	NULL
and	NULL
K.	NULL
Takada	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
enhancer-type	NULL
sequence	NULL
that	NULL
is	NULL
responsive	NULL
to	NULL
Z	NULL
and	NULL
R	NULL
frans-activators	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Virology	NULL
172	NULL
:	NULL
655-658	NULL
.	NULL

Sixby	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
J.	NULL
G.	NULL
Nedrud	NULL
,	NULL
N.	NULL
Raab-Traub	NULL
,	NULL
R.	NULL
A.	NULL
Hanes	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pagano	NULL
.	NULL

1984	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
replication	NULL
in	NULL
oropharyn-geal	NULL
epithelial	NULL
cells	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

310:1225-1230	NULL
.	NULL

Takada	NULL
,	NULL
K.	NULL
,	NULL
N.	NULL
Shimizu	NULL
,	NULL
S.	NULL
Sakuma	NULL
,	NULL
and	NULL
Y.	NULL
Ono	NULL
.	NULL

1986	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
genome	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
EBV	NULL
DNA	NULL
fragment	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

57:1016-1022	NULL
.	NULL

Tonneguzzo	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
C.	NULL
Hayday	NULL
,	NULL
and	NULL
A.	NULL
Keating	NULL
.	NULL

1986	NULL
.	NULL

Electric	NULL
field-mediated	NULL
DNA	NULL
transfer	NULL
:	NULL
transient	NULL
and	NULL
stable	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
lymphoid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:703-706	NULL
.	NULL

Urier	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
P.	NULL
Chambard	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
protein	NULL
EB1l	NULL
activates	NULL
transcription	NULL
from	NULL
different	NULL
responsive	NULL
elements	NULL
including	NULL
AP-1	NULL
binding	NULL
sites	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1447-1453	NULL
.	NULL

Vinson	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
P.	NULL
B.	NULL
Sigler	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1989	NULL
.	NULL

Scissors-grip	NULL
model	NULL
for	NULL
DNA	NULL
recognition	NULL
by	NULL
a	NULL
family	NULL
of	NULL
leucine	NULL
zipper	NULL
proteins	NULL
.	NULL

Science	NULL
246:911-916	NULL
.	NULL

Wong	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
A.	NULL
Levine	NULL
.	NULL

1986	NULL
.	NULL

Identification	NULL
and	NULL
mapping	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
antigens	NULL
and	NULL
demonstration	NULL
of	NULL
a	NULL
viral	NULL
gene	NULL
activator	NULL
that	NULL
functions	NULL
in	NULL
trans	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

60:149-156	NULL
.	NULL

